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Protein quality control mechanisms are vital in maintaining correct levels of functional 
proteins in a crowded intracellular milieu. These mechanisms recognise proteins in their 
non-native state and triage such candidates for either rescue, or channel them towards 
pathways that lead to their degradation. In the case of secretory and membrane proteins 
that mislocalize to the cytosol (MLPs), and of newly synthesised tail-anchored (TA) 
membrane proteins, their exposure of otherwise buried hydrophobic residues 
necessitates a mechanism of shielding such residues from the aqueous cytoplasm. This 
task is carried out by the collective actions of SGTA (small, glutamine-rich, 
tetratricopeptide repeat protein alpha) and the heterotrimeric BAG6 (BCL2-associated 
athanogene 6) complex, that contribute to a SGTA/BAG6 quality control cycle that can 
direct hydrophobic substrates towards either ubiquitination and proteasomal degradation 
or productive membrane insertion.  
 
SGTA is a modular protein consisting of three domains, an N-terminal dimerisation 
domain, a central TPR domain, and a substrate binding C-terminal domain. The aim of 
this thesis is to characterise full-length SGTA using a range of biophysical techniques, 
with an emphasis to understand its C-terminal domain, molecular details of which 
remain elusive. In addition, this work aims to uncover how SGTA interacts with its 
hydrophobic substrates, underlying its role in enforcing cytosolic quality control. To 
this end, a combination of nuclear magnetic resonance (NMR) spectroscopy and native 
mass spectrometry experiments have identified a constrained conformation of SGTA in 
solution mediated by C-terminal dimerisation, and circular dichroism (CD) 
spectroscopy has revealed the presence of alpha helical regions within the C-terminal 
domain. Furthermore, fluorine-19 NMR has been used to investigate the interaction of 
TA proteins with the C-terminal domain of SGTA. Finally, results presented herein 
establish that SGTA interacts with the intrinsic proteasomal ubiquitin receptor Rpn13 
via a two-carboxylate clamp mode of molecular recognition, and this interaction has 
been characterised by solution NMR spectroscopy, size exclusion chromatography, 
isothermal titration calorimetry (ITC) and mutagenesis experiments, to uncover details 
of a potential SGTA/BAG6 quality control cycle operating at the 19S regulatory particle 
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1.1 Protein homeostasis and macromolecular quality control 
‘Homeostasis’ refers to the ability of living organisms to maintain a constant internal 
environment, a term devised by Walter Cannon to describe the physiological processes 
responsible for the maintenance of consistent internal chemistry (such as pH, ionic 
strength, electrolyte composition, temperature, and others) required to sustain life 
(Cannon, 1939). The concept of homeostasis dates back to the French physiologist 
Claude Bernard’s theory of the ‘milieu intérieur’, which states ‘The constancy of the 
internal environment is the condition of a free and independent existence’ (Bernard, 
1878). This concept has been extended to proteins, the workhorses of a cell. Nascent 
polypeptides synthesized by the ribosome fold into precise three-dimensional structures 
to carry out their prescribed functions, and importantly must maintain their structure for 
the duration of their functional lifetime. However, it must be noted that not all proteins 
require a precise three-dimensional fold to function, such is the case for intrinsically 
disordered proteins and molten globules (Dyson and Wright, 2005; Redfield, 1999). 
Thus cellular ‘protein homeostasis’ is effected by an integrated network of molecular 
chaperones and proteases, together with components of the autophagy system, that 
maintain quality control over protein structure and facilitate the removal of terminally 
misfolded and aggregated proteins (Hartl et al., 2011; Wickner et al., 1999). 
 
For many small proteins the information contained in their amino-acid sequence is 
sufficient to attain their correct three-dimensional structure in vitro (Anfinsen, 1973; 
Dobson et al., 1998). However, in a cellular context many proteins require the 
assistance of molecular chaperones for proper folding to occur on biologically relevant 
timescales (Hartl, 1996). The term ‘molecular chaperone’ was coined by Ron Laskey to 
describe the ability of the nucleoplasmin protein to prevent histone aggregation with 
DNA during nucleosome assembly (Laskey et al., 1978), and some years later was used 
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to describe cellular proteins that mediated the folding and assembly of other polypeptide 
chains (Ellis, 1987). Thus molecular chaperones promote protein folding, and can be 
defined as ‘any protein that interacts with, stabilizes or helps another protein to acquire 
its functionally active conformation, without being present in its final structure’ (Hartl 
et al., 2011; Hartl, 1996). As protein concentrations in human cells can range from 50 to 
300 mg/ml (Wolff et al., 2014), it is unsurprising that a myriad of chaperone networks 
have evolved to reduce aggregation and maintain proteins in functionally active 
conformations in such crowded cellular environments. 
 
Molecular chaperones belong to a family of proteins referred to as heat-shock proteins 
(Hsps). Hsps are present in all domains of life, first appearing in primitive 
hyperthermophilic archaea, in which their role was to exert cytoprotective effects during 
conditions of elevated temperatures (therefore called ‘heat-shock’ proteins). As the 
family diverged into more developed species, its role has been modified into that of a 
stress-protein which protects cells from physiological and environmental stress, during 
which their expression is upregulated (Haslbeck et al., 2005). These chaperones 
typically recognize surface-exposed hydrophobic regions exposed by non-native 
proteins, such as folding intermediates and misfolded proteins, frustrating their 
aggregation and preventing them from degradation. Chaperones such as the Hsp70s, 
Hsp90s and chaperonins (Hsp60s) promote folding of client proteins via ATP 
dependent cycles of binding and release (Hartl et al., 2011). On the other hand, ATP 
independent molecular chaperones such as the small heat shock proteins (sHsps) act as 
‘holdases’ preventing client aggregation before handover to ATP dependent chaperones 
can take place (Clark et al., 2012).  
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When molecular chaperones fail to rescue clients by promoting their biologically active 
conformations, energy-dependent proteases eliminate such irreversibly damaged 
proteins via the ubiquitin-proteasome system (UPS) (Komander and Rape, 2012). It is 
important to consider that the UPS cannot limit its remit to the recognition of terminally 
misfolded proteins, as it also has to eliminate folding intermediates that fail to achieve 
their native conformations (Rodrigo-Brenni and Hegde, 2012). Consequently, target 
selection during protein quality control presents a formidable challenge to cellular 
proteostasis networks, and the kinetics of partitioning between chaperones and the UPS 
machinery has been suggested to play a role in deciding the fate of client proteins (Shao 
and Hegde, 2016; Wickner et al., 1999).   
 
When cellular quality control options fail, this subsequently leads to the accumulation 
of intracellular aggregates, a process that has been associated with many disease 
phenotypes (Powers et al., 2009). Diseases associated with the failure of cellular protein 
quality control include neurodegeneration, cardiovascular disease, lung disease, 
metabolic disorders, and certain cancers (Powers et al., 2009; Chiti and Dobson, 2006). 
In particular, neurodegenerative phenotypes appear to be closely linked to failures in the 
cellular quality control machinery, possibly due to the fact that neurons are long-lived 
cells and are more susceptible to the accumulation of aberrant proteins over time (Shao 
and Hegde, 2016).  
 
1.2 The proteostasis network 
The cellular proteostasis network (Fig. 1.1) is an extensive network of quality control 
factors consisting of around 200 chaperones and co-chaperones, and around 600 UPS 
and autophagy components. Chaperones exert their effects in maintaining proteostasis 
by promoting protein folding in collaboration with co-chaperones (such as AHA1 and 
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SGTA), and other regulatory cofactors such as the BCL2-associated athanogene (BAG) 
family of proteins (Hartl et al., 2011).  
 
On the other hand, irreversibly misfolded proteins are subjected to proteolytic 
degradation via the UPS system, which involves the covalent attachment of ubiquitin 
molecules to lysine residues on substrates via an isopeptide bond, which marks 
substrates for proteasome degradation (Komander and Rape, 2012). The 76-residue 
modifier protein ubiquitin is a highly stable protein that presents a compact β-grasp fold 
(Vijay-Kumar et al., 1987). The attachment of ubiquitin to proteins occurs through a 
cascade of sequential reactions catalysed by ubiquitin-activating (E1), ubiquitin-
conjugating (E2), and ubiquitin ligase (E3) enzymes. This E1/E2/E3 cascade leads to 
the formation of an isopeptide bond between the C-terminus of ubiquitin and a substrate 
lysine. Ubiquitin itself contains seven lysine residues which results in the formation of 
polyubiquitin chains. In particular, K48- and K11-linked polyubiquitin chains mark 
substrate proteins for proteasomal degradation (Komander and Rape, 2012). 
 
Whereas the degradation of misfolded protein by the UPS requires substrate 
ubiquitination together with mechanisms to keep clients soluble prior to elimination, it 
has been observed that terminally aggregated proteins can also be sequestered into 
perivacuolar inclusions for autophagy (Kaganovich et al., 2008). Autophagy is a major 
intracellular mechanism that facilitates the degradation of cytosolic components 
delivered to the lysosome (Mizushima and Komatsu, 2011). These aggregates are 
sequestered at sites close to the microtubule-organizing centre, and have been referred 
to as aggresomes, which are suggested to be less toxic to the cell (Hartl et al., 2011; 
Kopito, 2000). The proteostasis network thus ensures normal cellular physiology 







Figure 1.1- The proteostasis network. The proteostasis network consists of an 
extensive network of chaperones, along with the cellular machinery to degrade or 
sequester terminally misfolded proteins, thereby preventing the accumulation of toxic 
aggregates in the cytosol. In mammalian cells, there are around 180 different chaperone 
components, around 600 components of the ubiquitin-proteasome system (UPS) 
(including the E1/E2/E3 cascade of enzymes) that effect proteasomal degradation, and 
around 30 components of the autophagy system (Hartl et al., 2011). The co-chaperone 




1.3 Small glutamine-rich, tetratricopeptide repeat-containing protein alpha 
(SGTA) 
The small glutamine-rich, tetratricopeptide repeat-containing protein alpha (SGTA) is a 
co-chaperone involved in a specialized branch of the global cellular proteostasis 
network that decides the fate of secretory and membrane proteins that mislocalise to the 
cytosol (referred to as MLPs), facilitates the biogenesis of tail-anchored (TA) 
membrane proteins, and influences ER- associated degradation (ERAD) (Casson et al., 
2016; Wunderley et al., 2014; Xu et al., 2012; Hegde and Keenan, 2011). The ability of 
SGTA to modulate various protein quality control pathways in the cytosol is primarily 
due to its recognition of surface exposed regions of hydrophobicity (termed ‘degrons’) 
on newly synthesized and mislocalised proteins. As a result, SGTA shields these 
degrons from the surrounding aqueous cytosol, thereby preventing protein misfolding, 
aggregation, and the formation of aberrant protein-protein interactions. Upon 
stabilisation, these proteins can have different fates, such as being folded to their native 
state by molecular chaperones followed by targeting to their final correct destinations, 
or being marked for degradation by the ubiquitin-proteasome system (UPS). (Casson et 
al., 2016, Roberts et al., 2015). 
 
SGTA was first identified in complex with viral proteins (Callahan et al., 1998; 
Cziepluch et al., 1998), and is ubiquitously expressed across tissue types (Philp et al., 
2016). In addition to its roles in effecting macromolecular quality control and TA 
protein biogenesis, SGTA has been implicated in a wide-range of biological processes 
such as cell-division and apoptosis (Winnefeld et al., 2006), synaptic neurotransmitter 
release (Tobaben et al., 2001), viral lifecycles (Fielding et al., 2006; Handley et al., 
2001; Callahan et al., 1998), and in the regulation of hormone receptor signalling (Philp 
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et al., 2013; Buchanan et al., 2007). Thus SGTA is emerging as a co-chaperone of 
importance in diverse pathophysiological contexts underlying health and disease. 
 
1.4 Structural studies of SGTA  
SGTA is a 34 kDa protein that assembles as a homodimer, with each protomer 
consisting of three domains: a highly conserved N-terminal dimerization domain, 
followed a central tetratricopeptide (TPR) domain, and a C-terminal domain which 
contains three NNP repeat motifs and a glutamine rich region (Figs. 1.2 and 1.3) (Darby 
et al., 2014; Simon et al., 2013; Dutta and Tan, 2008; Liou and Wang, 2005). High 
resolution structural studies of SGTA, and its yeast equivalent Sgt2, have thus far 
focused on its N-terminal and TPR domains (Table 1.1). SGTA’s hydrophobic substrate 
binding capability, pertinent to its function in various quality control related scenarios, 
is mediated by its C-terminal domain. Hydrophobic substrates specifically recognised 
by the SGTA C-terminal domain in the cytosol include MLPs, the transmembrane 
domain (TMD) helices of newly synthesised TA-proteins, and aberrant membrane 
protein precursors (Casson et al., 2016; Hegde and Keenan, 2011). However, structural 
details of SGTA’s substrate-binding C-terminal domain remain poorly understood. 
Furthermore, as structural studies carried out to date have focused solely on isolated 
domains, a detailed picture of SGTA domain organisation and conformations in the 







Figure 1.2 – Schematic of full-length SGTA. The solution NMR structure of the N-
terminal domain of SGTA (PDB accession code: 4CPG) is shown as a dimer with the 
position of its UBL binding domain (UBD) indicated. The crystal structure of the 
central TPR domains (PDB accession code: 2VYI) are shown separated with the N-
terminal dimer by flexible linkers (dotted lines). Structural details of the C-terminal 
substrate-binding domain are yet to be determined.  
 
Table 1.1 - Summary of high-resolution structures of SGTA/Sgt2 domains 
 Domain Species Residues Technique PDB 
SGTA N-terminal 
(dimer) 
Homo sapiens 3-54 X-ray crystallography 4GOD 
  1-69 Solution NMR spectroscopy 4CPG 





1-78 Solution NMR spectroscopy 4ASV 
 Saccharomyces 
cerevisiae 
2-72 Solution NMR spectroscopy 2LXB 
TPR  Aspergillus 
fumigatus 
104-254 X-ray crystallography 3SZ7 
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Figure  1.3– SGTA sequence alignment (legend on next page).   
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Figure 1.3– SGTA sequence alignment. Sequences of SGTA and its homologs across 
the phyla have been aligned using Clustal Omega multiple sequence alignment. 
Domains have been annotated with reference to the human SGTA sequence. C. elegans 
and D. rerio have longer N-terminal extensions compared to both mammalian and yeast 
equivalents. The central TPR repeats appear to be the most conserved, however the TPR 
capping helix (helix 7) is much less conserved in fungal species when compared to 
metazoans. A glutamine-rich region, present in the C-terminal domain, is more 
conserved in metazoans. The presence of at least one NNP motif within the C-terminal 
domain is characteristic across all phyla, with duplication of such motifs occurring in 
higher metazoans. This sequence alignment was generated using Jalview (Waterhouse 
et al., 2009). 
 
1.4.1 N-terminal domain 
The N-terminal domain of SGTA exists as a homodimer in solution, with each protomer 
consisting of four α-helices connected by short loops. These protomers arrange into a 
unique helical fold (Fig. 1.4). The dimeric interface is stabilised by hydrophobic 
residues that form a tight interaction, reminiscent of the core of a globular protein 
(Darby et al., 2014). This characteristic N-terminal fold is conserved in the yeast 
homolog, Sgt2 (Simon et al., 2013). Furthermore, this N-terminal domain provides 
SGTA with a direct physical link to different subunits of the BAG6 complex, which 
underlies SGTA’s functionality in various cellular quality control pathways. Moreover, 
this is achieved through the SGTA N-terminal domain’s ability to interact with either of 
the two ubiquitin-like (UBL) domains present in the BAG6 complex (described in 
Section 1.5) (Darby et al., 2014; Simon et al., 2013).  
 
The ubiquitin-binding domain (UBD) of SGTA is formed by a negatively charged 
surface on its N-terminal domain dimer. This surface arises as a result of side-chain 
contributions from charged negatively charged residues that form the second alpha helix 
(α2) (Asp27, Glu30, Glu33, and Glu40) of each protomer within the dimer. As a result, 
each N-terminal dimer can recognize a single UBL domain (Figs. 1.4 and 1.5). This is 
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because UBLs characteristically exhibit a positively charged region (of up to 5 arginine 
or lysine residues), thus binding is mediated by electrostatic interactions (Darby et al., 
2014). 
 
Figure 1.4– SGTA N-terminal domain highlighting its UBL-binding domain 
(UBD). The solution NMR structure of the N-terminal domain dimer of SGTA (PDB 
accession code: 4CPG) is shown as orthogonal views. The dimer has a negatively 
charged surface with contributions from side-chains of Asp27, Glu30, Glu33, and 
Glu40 that form the UBD (shown in ball-and-stick format). This region facilitates the 
N-terminal domain dimer’s interaction with UBLs (from BAG6 and Ubl4a) mediated 





Figure 1.5- N-terminal domain of SGTA in complex with a cognate UBL. The UBD 
of the N-terminal dimer of SGTA (in blue) shown in complex with a cognate UBL 
domain (in green). Charged residues facilitating this electrostatic interaction at the 
binding interface shown as sticks. Inset shows two orthogonal views of the N-terminal 
dimer/UBL binding interface (PDB accession code: 4CPG) (Darby et al., 2014). 
 
1.4.2 TPR domain 
The central TPR domain of SGTA (hereafter referred to SGTA_TPR) consists of 
three structurally identical helix-turn-helix motifs, in which each pair of α-helices 
folds in an antiparallel fashion. These TPR motifs are followed by a C-terminal 
capping helix (α7) that packs against the second helix of the third motif (Fig. 1.6A). 
These seven helices arrange into a right-handed superhelical structure to form a 
concave surface lined by helices α1, α3, α5, and α7 (Dutta and Tan, 2008). In 
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addition, this concave surface forms a groove that consists of conserved basic 




Figure 1.6- The TPR domain of SGTA. (A) Crystal structure of the SGTA_TPR 
domain (PDB accession code: 2VYI), consisting of three helix-turn-helix repeats (α1/α2, 
α3/α4, α5/α6) followed by a capping helix (α7). (B) Basic residues in the TPR groove 
present on its concave surface (shown as sticks) provides a platform for protein-protein 
interactions, such as for the EEVD motifs of the Hsp70/90 molecular chaperones 
(shown as sticks) (Dutta and Tan, 2008). 
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The fold of human SGTA_TPR is highly similar to that of TPR domains present in 
other co-chaperones such as CHIP (the carboxyl-terminus of Hsp70 interacting protein) 
and HOP (Hsp70/90 organizing protein) (Dutta and Tan, 2008). Both CHIP and HOP 
TPR domains interact with C-terminal EEVD motifs of Hsp70 and Hsp90 molecular 
chaperones via a ‘two-carboxylate clamp’ mechanism of molecular recognition 
(Scheufler et al., 2000; Zhang et al., 2005). This mechanism is mediated by the 
conserved basic residues present in the TPR groove, that form a network of interactions 
to ‘clamp’ the two free C-terminal carboxylates present on the terminal aspartate of a 
Hsp70/90 EEVD motif (Scheufler et al., 2000). An overlay of crystal structures of 
SGTA_TPR with TPR domains of CHIP and HOP bound to EEVD peptides reveal that 
TPR residues essential to mediate such a ‘two-carboxylate clamp’ mode of molecular 
recognition are also present in SGTA_TPR (Dutta and Tan, 2008). This is indicative of 
human SGTA’s ability to associate with Hsp70/90 chaperones in a similar fashion as 
described for CHIP and HOP TPR domains (Fig 1.6B). Additionally, various 
independent studies have confirmed that SGTA_TPR interacts with Hsp70 and Hsp90 
chaperones, and these studies suggest that binding occurs via the chaperone EEVD 
motifs (Worrall et al., 2008; Liou and Wang, 2005; Liu et al., 1999). Therefore, it 
appears that SGTA_TPR provides a platform whereby it can interact with ATP-
dependent molecular chaperones, and this could provide SGTA bound substrates with 
access to rescue pathways enabling their acquisition of a native conformation.  
 
1.4.3 C-terminal domain 
SGTA’s function in quality control relies on its ability to recognise surface exposed 
regions of hydrophobicity presented by its substrates. This ability of SGTA to recognise 
hydrophobic degrons has been attributed to its C-terminal domain. The C-terminal 
domain of human SGTA consists of three NNP motifs, with at least the first NNP motif 
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conserved in the equivalent region of yeast Sgt2 (Fig. 1.3). NNP motifs have been 
proposed to support physical interactions within protein complexes (Casey et al., 2011), 
strongly indicative of a functional role in SGTA. The C-terminal domain of SGTA also 
consists of a glutamine-rich region, which comprises a stretch of around 39 amino acids 
interspersed with 12 glutamine residues (Fig. 1.3) (Liou and Wang, 2005).  
 
In agreement with its role in quality control, the SGTA C-terminal domain has been 
shown to interact with polypeptide fragments containing six or more consecutive 
hydrophobic residues, and with in vitro translated integral membrane protein of the rat 
type 1 glucose transporter (Liou and Wang, 2005). It is clear that the C-terminal domain 
is vital to SGTA’s function in triaging stray hydrophobic substrates in the cytosol. 
However, structural details describing this region of SGTA remain elusive. As a result, 
there are many outstanding questions regarding the nature and extent of this key 
substrate-binding domain of SGTA. These include mechanisms underlying the binding 
and release of different classes of mislocalised substrates and aberrant membrane 
protein precursors, mechanisms of TA-protein recognition and sorting, and details of 
SGTA’s participation in the ERAD pathway.  
 
1.5 The heterotrimeric BAG6 complex 
SGTA acts in concert with the heterotrimeric BAG6 complex to accomplish its roles in 
membrane protein quality control and in the biogenesis of tail-anchored proteins 
(Casson et al., 2016). The heterotrimeric BAG6 complex consists of the 
BAG6/BAT3/Scythe (BCL2-associated athanogene), TRC35 (transmembrane domain 
recognition complex 35) and Ubl4a (ubiquitin-like protein 4a) proteins. The BAG6 
protein itself consists of an N-terminal UBL domain, followed by a central proline rich 
region and a C-terminal BAG-similar domain (Fig. 1.7) (Mock et al., 2015; Mariappan 
et al., 2010). Based on our current understanding of BAG6, it is likely that its central 
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proline rich region interacts with hydrophobic substrates (Casson et al., 2016). 
Furthermore, it is known that the N-terminal UBL domain of the BAG6 protein can 
recruit quality control effectors such as SGTA (Darby et al., 2014) and the E3 ligase 
RNF126 (Krysztofinska et al., 2016; Rodrigo-Brenni et al., 2014) to act on its 
substrates. Furthermore, its C-terminal BAG-similar domain has distinct binding sites 
for the Ubl4a and TRC35 subunits of the heterotrimeric BAG6 complex, and promotes 
TA protein biogenesis (see Section 1.7) by effecting the transfer of precursor proteins to 
the ER targeting factor TRC40 (Mariappan et al., 2010).  
 
Structurally, the N-terminal domain of the BAG6 protein is a type II UBL domain. 
These UBL domains are highly similar to ubiquitin and are present as functional 
domains within proteins (Darby et al., 2014). The C-terminus of BAG6 is a BAG-
similar domain, and interacts with the C-terminal region of Ubl4a, therefore is also 
referred to as a TUGS (tethering Ubl4a to BAG-similar) domain. The BAG-similar 
domain of BAG6 consists of three α-helices, with a hydrophobic patch that docks 
against Ubl4a (Fig. 1.8) (Kuwabara et al., 2015). Unlike its N- and C-terminal domains, 
structural details with regard to the substrate-binding central proline-rich region of 
BAG6 remain to be elucidated. 
 
Functionally, the BAG6 complex was identified as an essential component involved in 
the chaperoning of TA proteins in the cytosol (Mariappan et al., 2010). It was 
subsequently implicated in the degradation of MLPs, whereby the BAG6 complex 
recognises regions of exposed hydrophobicity on MLPs and triages such clients down a 
degradative pathway (Hessa et al., 2011). It is now known that the BAG6 complex 
carries out ubiquitination of MLPs through the actions of the E3 ligase RNF126, 







Figure 1.7- The BAG6 complex. (A) Schematic of the heterotrimeric BAG6 complex. 
The TRC35 and Ubl4a proteins interact with the C-terminal domain of the BAG6 
protein. (B) BAG6 protein. The crystal structure of the N-terminal UBL domain of 
BAG6 shown in purple-blue (PDB accession code: 4EEW), this is followed by a central 
proline-rich region for which high-resolution structural details remain unknown. The C-
terminal BAG-similar domain (BAGS) is shown in red (PDB accession code: 4X86) 







Figure 1.8- TUGS domain of Ubl4a in complex with the BAG-similar domain of 
BAG6. Orthogonal views of the crystal structure of the C-terminal BAG-similar domain 
of BAG6 (in red) in complex with a Ubl4a fragment (in green) (PDB accession code: 
4X86) (Kuwabara et al., 2015).  
 
 
The BAG6 complex recruits the E3 ligase RNF126 via its N-terminal UBL domain. The 
N-terminal region of RNF126 folds into a zinc finger domain in which a zinc cation is 
coordinated by four cysteine residues. This zinc finger region serves as a platform for its 
interaction with the UBL domain of the BAG6 protein (Fig. 1.9) (Krysztofinska et al., 
2016). As E3 ligases, together with their cognate E2 and E1 enzymes, catalyse the 
covalent attachment of ubiquitin to their substrates, RNF126 provides a link between 
the BAG6 complex and the ubiquitin proteasome system (UPS) allowing terminally 







Figure 1.9- The BAG6 UBL domain in complex with the N-terminal zinc finger 
domain of the E3 ligase RNF126. The BAG6 UBL domain is shown in blue, and the 
N-terminal zinc finger region of RNF126 is shown in orange, both in cartoon 
representation. (A) Network of hydrogen bonded and electrostatic interactions at the 
complex interface (B) Hydrophobic interactions driving complex formation (PDB 
accession code: 2N9P) (Krysztofinska et al., 2016). 
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1.6 The SGTA/BAG6 cycle of MLP quality control  
As a result of inefficiencies inherent in the targeting and translocation of newly 
synthesised proteins to the ER, a certain fraction of these proteins default to the cytosol 
(Levine et al., 2005). In the cytosol, these mislocalized secretory and membrane 
proteins (MLPs) expose hydrophobic regions such as signal sequences and 
transmembrane domains, eventually leading to their aggregation. Furthermore, once 
these intracellular aggregates form, they can promote the aggregation of other 
functional proteins in a cell (Chakrabarti and Hegde, 2009). Thus specific quality 
control pathways have evolved in metazoans that lead to the degradation of MLPs that 
fail to reach their final cellular destinations, preventing MLP aggregates from 
accumulating in the cytosol. In particular, SGTA operating in tandem with the BAG6 
complex constitutes the SGTA/BAG6 cycle of quality control (Fig 1.10), which 
determines the fate of stray hydrophobic substrates in the cytosol (Wunderley et al., 
2014; Leznicki et al., 2013; Leznicki and High, 2012; Hessa et al., 2011; Mariappan et 
al., 2010). 
 
Both SGTA and the BAG6 complex interact with a similar set of hydrophobic 
substrates in the cytosol that include TA proteins and MLPs. Furthermore, in the 
SGTA/BAG6 cycle, hydrophobic substrates can be transferred between SGTA and 
BAG6 (Casson et al., 2016). On one hand, SGTA directs bound MLPs towards 
deubiquitination and hence stabilisation (Wunderley et al., 2014; Leznicki and High, 
2012). This would allow viable substrates with a further opportunity at productive 
folding, and to engage with the corresponding targeting machinery for ER delivery. On 
the other hand, the BAG6 complex directs MLPs towards polyubiquitination followed 
by proteasomal degradation (Hessa et al., 2011; Mariappan et al., 2010). Thus for 
terminally misfolded MLPs and TA proteins, the BAG6 complex triages them onto a 
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degradative route. Likewise, for prematurely ubiquitinated TA proteins, SGTA 
dependent deubiquitination could precede transfer to the Ubl4a/TRC35 subunits of the 
BAG6 complex for TRC40 dependent membrane targeting (see Section 1.7).  
 
Therefore, SGTA is intimately linked with the quality control function of the BAG6 
complex in deciding the fate of hydrophobic substrates such as MLPs and TA proteins, 
by either promoting them towards ER delivery or marking them for proteasomal 
degradation (Wunderley et al., 2014; Leznicki et al., 2013; Leznicki and High, 2012; 
Hessa et al., 2011). SGTA facilitates this process by promoting MLPs towards the 
BAG6 complex, thereby preventing formation of protein aggregates. In the case of 
terminally misfolded substrates, the BAG6 complex recruits the E3 ubiquitin ligase, 
RNF126, to mark such MLPs or aberrant precursors for proteasomal degradation 
(Rodrigo-Brenni et al., 2014). Likewise, SGTA is capable of reversing ubiquitination 
caused by the BAG6 complex via an as yet unidentified deubiquitinating enzyme 
thereby rescuing proteins from degradation (Leznicki and High, 2012). Therefore, the 
SGTA/BAG6 cycle constitutes several successive cycles of substrate ubiquitination and 
deubiquitination, the outcome of which will eventually decide the fate of MLPs and TA 








Figure 1.10- The SGTA/BAG6 cycle of quality control in the cytosol. SGTA 
promotes  the deubiquitination and stabilisation of MLP substrates, while the BAG6 
complex promotes their ubiquitination via the E3 ubiquitin ligase RNF126. BAG6 
directs TA protein precursors to the TRC40 targeting factor, which facilitates their ER 
delivery. (Wunderley et al., 2014; Rodrigo-Brenni et al., 2014; Leznicki et al., 2013; 
Leznicki and High, 2012; Hessa et al., 2011) 
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1.7 SGTA in Get/TRC pathways of TA membrane protein insertion 
Integral membrane proteins participate in a diverse range of cellular activities. They 
consist of hydrophobic transmembrane regions (TMDs), and are synthesised in the 
cytoplasm, which necessitates a mechanism whereby they are protected from the 
aqueous cytosolic environment to ensure targeted delivery and integration into their 
membrane residences. Most membrane proteins access the signal recognition particle 
(SRP) dependent co-translational pathway, in which a SRP bound ribosome-nascent 
chain complex is passed on to the Sec61 translocon, which subsequently facilitates 
membrane integration (Rapoport, 2007). However, for the tail-anchored (TA) family of 
membrane proteins, this co-translational pathway turns out to be sterically inaccessible. 
TA proteins are characterised by the presence of a functional cytoplasmic domain 
tethered to the lipid bilayer by a single pass TMD helix present at their extreme C-
terminus, a region which also includes their membrane targeting signal (Hegde and 
Keenan, 2011). These TA proteins constitute around five percent of all human 
membrane proteins, to include SNAREs, ER translocon components and signalling 
proteins (Simpson et al. 2010). TA proteins cannot access the co-translational pathway 
because their TMD helix will still be present within the ribosomal exit tunnel as 
translation nears completion. Therefore an alternative, SRP independent, conserved 
post-translational membrane insertion pathway referred to as the mammalian TRC 
(transmembrane domain recognition complex) pathway is employed by TA proteins for 
their correct targeting and integration into the lipid bilayer of the endoplasmic reticulum 
(ER) (Hegde and Keenan, 2011). The existence of this SRP and translocon independent, 
post-translational insertion process, was first demonstrated with the SNARE protein 
synaptobrevin by Kutay et al. (1995). However, details pertaining to this post-
translational pathway began to emerge with the discovery of the mammalian cytosolic 
ATPase TRC40 (40 kDa subunit of the transmembrane domain recognition complex), 
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which was identified to be the central targeting factor of TA proteins to the ER 
(Stefanovic and Hegde, 2007).  
 
An early step in the mammalian TRC pathway involves the interaction of TMD helices 
of TA proteins with SGTA, which acts as a pre-targeting factor. SGTA bound TA 
proteins are then handed over to the TRC40 ATPase as a result of the concerted actions 
of the SGTA/BAG6 cycle (Mock et al., 2015; Leznicki et al., 2010; Mariappan et al., 
2010). The BAG6 protein acts a scaffold for Ubl4a and TRC35 that together ensure 
effective TA substrate handover from SGTA to TRC40 (Fig. 1.11). The TA-substrate 
bound TRC40 is then delivered to the ER via its cognate receptor formed by a 
heterodimeric membrane protein complex of WRB (tryptophan-rich basic protein) and 
CAML (calcium-modulating cyclophilin ligand) (Fig. 1.11) (Yamamoto and Sakisaka, 
2012; Vilardi et al., 2011; Schuldiner et al., 2008).  
 
In yeast, the equivalent TA insertion pathway is referred to as the guided entry of tail-
anchored proteins (Get) pathway (Simpson et al. 2010). The Get pathway involves 
handover of TA protein substrates bound to the Sgt2 co-chaperone (the yeast equivalent 
of SGTA) to the Get3 ATPase (the yeast equivalent of TRC40), a process mediated by 
the Get4/Get5 complex (homologous to mammalian TRC35 and Ubl4a). Also, there is 
no yeast equivalent of the BAG6 protein, however the Get4/Get5 complex is sufficient 
to ensure substrate transfer from Sgt2 to Get3 (Casson et al., 2016). This is followed by 
subsequent TA-protein release at the ER membrane by the Get1/Get2 receptor complex 
(the yeast equivalent of mammalian WRB and CAML proteins). Moreover, the Get1/2 
receptor complex has been shown to function as a membrane insertase specific for TA 





Figure 1.11– The TRC pathway of TA protein insertion. The TMD helices of newly 
synthesised TA membrane proteins are shielded from the aqueous cytosol by SGTA. 
These proteins are then passed on via the heterotrimeic BAG6 complex to the TRC40 
ATPase, which is the central targeting machinery for TA protein insertion. Finally, the 
TRC40 bound TA protein is handed over to the CAML/WRB receptors for membrane 





Figure 1.12- Get3 ATPase. The Get3 ATPase is the yeast equivalent of mammalian 
TRC40. The Get3 homodimer transitions from an ‘open’ to a ‘closed’ state, driven by 
ATP binding and contributions from the Get4/5 complex, in order to capture a TMD 
helix of a TA protein from Sgt2. The groove at the dimer interface effectively buries 
regions of hydrophobicity presented by the TMD helix. The Get3 homodimer is shown 
in surface representation, and the TMD helix from the TA protein Pep12 in the ‘closed’ 
state is shown in cartoon representation. (PDB accession codes: 5BW8 for ‘open’ and 
4XTR for ‘closed’ states) (Mateja et al., 2015). 
 
Additionally, structures of the central targeting component of the yeast Get pathway, the 
Get3 ATPase, have been solved in different nucleotide-bound states and conformations, 
with the apo ‘open’ conformation being the ATP-free state. (Gristick et al., 2015; 
Simpson et al., 2010). More recently, a crystal structure of the Get3 ATPase homodimer 
in complex with the TMD helix of a TA protein has revealed that ATP binding 
stabilizes a ‘closed’ conformation of Get3. In this ‘closed’ conformation the Get3 
homodimer exposes a large hydrophobic groove, capable of interacting with the TMD 
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helix of the TA protein (Fig. 1.12) (Mateja et al., 2015). This conformation of Get3 
protects that hydrophobic TMD helix from the surrounding aqueous cytosol and ensures 
the delivery of its TA cargo to the ER via the association of substrate-loaded 
Get3/TRC40 with cytosolic domain of CAML/Get2. Subsequent ATP hydrolysis is 
required to expose the WRB/Get1-binding site of Get3/TRC40	   leading to TA protein 
release and integration into the ER (Kubota et al., 2012; Mariappan et al., 2011; Stefer 
et al., 2011). 
 
Thus far, the TRC/Get pathway has been known as the main SRP-independent ER 
targeting pathway facilitating the post-translational membrane insertion of TA proteins. 
Recently, a novel SRP-independent membrane targeting pathway has been identified 
called the SND (for SRP-independent targeting) pathway (Aviram et al., 2016). This 
newly discovered SND pathway has been shown to be capable of compensating for the 
loss of SRP-dependent or TRC/Get pathways. Moreover, it has been suggested that the 
SND pathway functions in parallel to the TRC/Get pathways in targeting proteins with 
C-terminal hydrophobic regions (such as TA proteins) (Aviram et al., 2016). 
Additionally, other cytosolic factors such as the ubiquilin family of proteins have also 
been shown to chaperone TMD helices of both TA and non-TA proteins. (Itakura et al., 
2016). In particular, ubiquilins have been proposed to be major TMD binding proteins 
acting on precursors destined for the mitochondrial membrane (Itakura et al., 2016). It 
is thus clear that different cytosolic pathways exist to chaperone vulnerable TMD 
regions on newly synthesised proteins. The possibility of further yet to be identified 
targeting factors could add to what appears to be a robust network of cytosolic pathways 




1.8 SGTA and the ERAD pathway 
Terminally misfolded proteins in the ER are removed by a process referred to as ER- 
associated degradation (ERAD). ERAD encompasses protein quality control pathways 
within the ER that facilitate the removal of misfolded substrates by promoting their 
retrotranslocation into the cytosol, which is followed by ubiquitin mediated proteasomal 
degradation. This process is facilitated by the gp78/Hrd1 membrane-bound E3 ubiquitin 
ligase together with the retrotranslocation driving p97 ATPase (Stein et al., 2014; Xu et 
al., 2012; Wang et al., 2011). In the cytosol, ERAD substrates are known to interact 
with BAG6, which maintains them in a soluble state (Payapilly and High, 2014; Wang 
et al., 2011). This process is facilitated by the recruitment of SGTA to the BAG6 
complex via Ubl4a, which has been shown to play a role in maintaining the solubility of 
retrotranslocated substrates in the cytosol preventing their aggregation, thereby 
promoting ERAD (Fig. 1.13) (Xu et al., 2012). Hence it is apparent that SGTA, in 
collaboration with BAG6, can influence the fate of substrates destined for ERAD 




Figure 1.13- SGTA in the ERAD pathway. SGTA together with the BAG6 maintains 
the solubility of ERAD substrates in the cytosol. This is mediated by the Ubl4a 
dependent recruitment of SGTA to BAG6 (Xu et al., 2012).   
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1.9 SGTA mediated quality control at the proteasome 
In a recent study by Leznicki et al. (2015), it has been shown that SGTA is recruited to 
the 26S proteasome via the intrinsic proteasomal receptor Rpn13. This interaction was 
first identified by a yeast two-hybrid screen, and further pull-down assays showed that 
the C-terminal domain of Rpn13 was the SGTA interacting region. The same study also 
demonstrated that the association of exogenous SGTA to Rpn13 could lead to an 
increase in the steady-state MLP levels. This provides new evidence of SGTA 
dependent modulation of MLP quality control occurring at the proteasome. 
 
1.9.1 The 26S proteasome 
The 26S proteasome is the cellular machinery that degrades proteins conjugated to 
ubiquitin. It consists of a barrel shaped 20S core where proteolysis occurs, and has its 
ends capped by 19S regulatory particles that control substrate entry (Fig. 1.14). The 19S 
regulatory particles contain receptors for ubiquitin that in turn interact with 
ubiquitinated substrates and shuttle receptors. Substrates bound to the 19S particle are 
then translocated to the 20S core for degradation (Finley et al., 2016). Substrates 
delivered to the 19S particle are ultimately recognised by the one of its three intrinsic 
proteasomal ubiquitin receptors namely Rpn1 (Shi et al., 2016), Rpn10 (Deveraux et 
al., 1994) and Rpn13 (Husnjak et al., 2008). Also, the 19S particle consists of 
deubiquitinating enzymes (DUBs) that reverse ubiquitination thus generating free 
ubiquitin available for conjugation. These DUBs are Ubp6/Usp14, which binds to Rpn1 
(Shi et al., 2016) and UCH-L5/Uch37 (Lam et al., 1997) that binds to a deubiquitinase 
adaptor (DEUBAD) domain of Rpn13 (Sahtoe et al., 2015, VanderLinden et al., 2015). 
Once ubiquitin molecules are removed from substrates by one of these DUBs, a 
heterohexameric ring of AAA ATPase proteins present within the 19S particle (Rpt1-
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Rpt6) is responsible for the unfolding followed by translocation of substrates into the 




Figure 1.14- The 26S proteasome. The 26S proteasome is a multiprotein complex that 
comprises a barrel shaped 20S core where proteolysis occurs, capped at either end by a 
19S regulatory particle that controls substrate entry (Huang et al., 2016; PDB accession 
code: 5GJR).  
 
1.9.2 The intrinsic proteasomal ubiquitin receptor Rpn13 
Rpn13 is a major proteasomal ubiquitin receptor that consists of an N-terminal 
pleckstrin-like receptor for ubiquitin (Pru) domain that binds to both ubiquitinated 
substrates and the proteasome, and a conserved C-terminal deubiquitinase adaptor 
(DEUBAD) domain that binds to the UCH-L5 (UCH37) deubiquitinating enzyme 
(Chen et al., 2010). Rpn13 is thus capable of facilitating substrate delivery to the 
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proteasome via its N-terminal Pru domain. This occurs as a result of the Pru domains 
ability to directly interact with conjugated ubiquitin chains and with shuttle factors. 
However, when not bound to the proteasome, the Pru and DEUBAD domains associate 
with each other consequently lowering Rpn13’s affinity for ubiquitin (Fig. 1.15) (Chen 




Figure 1.15- Structure of full-length human Rpn13. Human Rpn13 consists of an N-
terminal pleckstrin-like receptor for ubiquitin (Pru) domain that binds to both 
ubiquitinated substrates and the proteasome (PDB accession code: 2KR0), a flexible 
linker, a conserved C-terminal deubiquitinase adaptor (DEUBAD) domain that binds to 
the UCH-L5 (UCH37) deubiquitinating enzyme which is followed by a flexible C-
terminal extension. When not bound to the proteasome, the Pru and DEUBAD domains 
associate with each other consequently lowering Rpn13’s affinity for ubiquitin (PDB 
accession code: 2KR0) (Chen et al., 2010).  
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Binding of Rpn13 to the 19S regulatory particle of the proteasome abrogates the 
interdomain association between its Pru and DEUBAD domains. This results in Rpn13 
activation and thereby offers ubiquitinated substrates unimpeded access to its Pru 
domain (Fig. 1.16) (Chen et al., 2010). The subsequent interaction of ubiquitin with the 
Pru domain is rather novel, with loop regions involved in the binding as opposed to 




Figure 1.16- Rpn13 activation upon binding to the proteasome. Binding of Rpn13 to 
the Rpn2 subunit at the 19S regulatory particle leads to a dissociation between Rpn13’s 
Pru and DEUBAD domains. This gives ubiquitinated substrates access to Rpn13 via its 
Pru domain (PDB accession code: 2KR0). Also, upon binding to the proteasome, Rpn13 
can interact with the UCH-L5 (UCH37) deubiquitinase via its DEUBAD domain (PDB 
accession code: 4UEM) (Sahtoe et al., 2015; Chen et al., 2010).  
 
Furthermore, activation of Rpn13 at the proteasome will also enable UCH-L5/UCH37 
binding to its C-terminal DEUBAD domain (Fig. 1.16), thus enabling the UCH-L5 
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deubiquitinase to access potential substrates (Sahtoe et al., 2015, VanderLinden et al., 
2015). From a structural point of view, the Rpn13 DEUBAD domain exists as a 
compact 8-helical bundle in its apo state (Chen et al., 2010) (Fig. 1.15). This helical 
bundle is fractured to accommodate the C-terminal region of UCH-L5/UCH37 as 
evident from crystal structures of the UCH-L5/DEUBAD complex (Fig. 1.16) (Sahtoe 
et al., 2015, VanderLinden et al., 2015). Thus it is apparent that SGTA’s interaction 
with the C-terminal domain of Rpn13 is likely to have implications regarding the 
ultimate fate of ubiquitinated MLPs that arrive at the proteasome. 
 
In addition to ubiquitin chains and shuttle receptors binding to the Rpn13 Pru domain, it 
has recently been discovered that the E3 ubiquitin ligase parkin can be recruited to the 
proteasome via an interaction with the Pru domain. In addition, this association with the 
proteasome can modulate parkin activity (Aguileta et al., 2015). It is therefore possible 
for both SGTA and parkin to be present simultaneously at the 19S particle, however the 
significance of this finding is yet to be understood. As mutations in parkin have been 
associated with a familial form of Parkinson’s disease (Aguileta et al., 2015), exploring 
possible effects of SGTA on parkin function might be of future interest.  
 
1.10 SGTA in health and disease 
SGTA has been implicated in the pathogenesis of many human diseases including 
various cancers, hormonally induced disease states, and neurodegenerative disorders. 
Thus far, malignancies associated which SGTA include cancers of the prostate (Trotta 
et al., 2013; Buchanan et al., 2007), ovary (Butler et al., 2013), breast (Zhu et al., 
2014), liver (Lu et al., 2014) and oesophagus (Yang et al., 2014). SGTA has also been 
associated with the pathogenesis of the hormone-related polycystic ovary syndrome 
(Goodarzi et al., 2008). In addition, SGTA has been linked to suppression of toxicity 
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associated with human beta amyloid expression (Fonte et al., 2002), and has been 
implicated in prion diseases (Kiktev et al., 2012). As evidence of SGTA’s engagement 
in various disease processes is rapidly emerging, further investigations will be required 
to improve our understanding of its involvement in aforementioned pathologies. 
 
1.11 SGTA in hormone receptor signaling 
SGTA is involved in steroid hormone receptor signalling via its association with the 
androgen receptor (Paul et al., 2014). The androgen receptor is a nuclear transcription 
factor and associated signaling pathways are implicated in the pathogenesis of 
hormonally induced disease states, including prostate and breast cancers. Interestingly, 
SGTA has been found to be upregulated in such disease states (Goodarzi et al., 2008; 
Buchanan et al., 2007; Zhu et al., 2014). It has been suggested that SGTA is recruited to 
the androgen receptor via the SGTA_TPR domain (Buchanan et al., 2007). 
Additionally, the Rec protein, a member of endogenous retroviruses of the HERV-K 
(HML-2) family, has been suggested to regulate androgen receptor activity mediated by 
an interaction with SGTA (Hanke et al., 2013).  
 
Furthermore, SGTA has been implicated in pathways that involve endocytosis of the 
growth hormone receptor, and in the regulation of glucocorticoid and progesterone 
receptor activity (Paul et al., 2014; Schantl et al., 2003). With regard to SGTA 
dependent hormone receptor regulation in general, it has been observed that depletion of 
SGTA in cells enhances receptor activity, whilst SGTA overexpression leads to 
suppression of receptor function (Paul et al., 2014). However, in the absence of a 
detailed characterisation of direct interactions between these components, precise 





1.12 The role of SGTA in viral lifecycles 
SGTA was discovered in complex with a nonstructural protein of parvovirus H-1 (NS1) 
and was suggested to play a role in viral replication and gene expression (Cziepluch et 
al., 1998). More recently, SGTA has been identified to associate with the SARS-CoV 
7a (severe acute respiratory syndrome coronavirus 7a) protein, and has been suggested 
to be involved in SARS-CoV virus particle assembly (Fielding et al., 2006). Also, 
SGTA is involved in promoting viral infections by facilitating ER membrane 
penetration, as observed for the nonenveloped simian virus 40 (SV40) (Walczak et al., 
2014). 
 
In addition, SGTA can influence human immunodeficiency virus type 1 (HIV-1) 
particle release (Waheed et al., 2016; Handley et al., 2001). HIV-1 is the causative 
agent of AIDS, and SGTA has been identified as a binding partner of the HIV-1 
accessory protein Vpu, and of the HIV-1 structural polyprotein Gag (Dutta and Tan, 
2008; Handley et al., 2001; Callahan et al., 1998). SGTA overexpression can inhibit 
HIV-1 particle release. Moreover, SGTA’s interaction with the HIV-1 Gag protein has 
been suggested to be responsible for this inhibitory effect. However, in the presence of 
Vpu, SGTA’s interaction with Gag is abolished, thus allowing HIV-1 particle release 
(Dutta and Tan, 2008; Handley et al., 2001; Callahan et al., 1998). Hence it is clear that 
SGTA plays a role in viral lifecycles, however mechanistic details underlying SGTA’s 




1.13 Aims of work described in this thesis 
SGTA is emerging as a key effector in a wide-range of biological processes, with 
fundamental roles in MLP quality control and TA protein biogenesis. However, 
structural and biophysical studies carried out on SGTA thus far have not been able to 
address its full-length assembly and conformations. Therefore work described in this 
thesis aims to characterise full-length SGTA in vitro, with a particular focus on its 
substrate binding C-terminal domain, molecular details of which remain poorly 
understood (Chapter 3). Also, it is important to study how SGTA binds to its 
hydrophobic substrates via its C-terminal domain, as this is pivotal to its role in 
enforcing cytosolic quality control. Thus Chapter 4 investigates the interaction of SGTA 
with hydrophobic substrates, to understand how SGTA, in particular its C-terminal 
domain, recognises exposed regions of hydrophobicity on tail-anchored membrane 
proteins destined for the Get/TRC pathway of membrane insertion. In addition, recent 
work has suggested that recruitment of SGTA to the 26S proteasome modulates quality 
control of hydrophobic substrates (Leznicki et al., 2015). Thus biophysical 
characterisation of the interaction between SGTA and the intrinsic proteasomal receptor 
Rpn13 is described in Chapter 5 with an aim to further our understanding as to how an 
SGTA-dependent quality control cycle may operate at the proteasome. Overall, this 
thesis aims to uncover molecular details underlying SGTA’s role in contributing to 






















All chemicals used were of laboratory grade.  
 
2.2 Water 
A Milli-Q Academic purification system (Millipore Ltd, Watford, U. K.) was used to 
purify de-ionised water by reverse osmosis. This was achieved by passing water through 
a 0.22 µm filter to produce ultra-pure water. Milli-Q purified water was used in the 
preparation of all aqueous solutions. 
 
2.3 Synthetic genes 
Synthetic genes were obtained as GeneArt™ Strings DNA Fragments (Thermo Fisher 
Scientific). These DNA fragments were codon optimised for expression in E. coli.  
 
2.4 Synthetic DNA oligonucleotides 
Short DNA oligonucleotides used as primers for PCR amplification of DNA fragments 
for plasmid cloning were synthesised by Integrated DNA Technologies (IDT).   
 
2.5 Vectors and plasmids 
The home-modified pET28 vector derived from the commercially available pET28 
vector (Novagen) used for generating various constructs used in this study, together 
with the plasmid encoding recombinant TEV protease were provided by Dr J.M. Pérez-




2.6 E. coli strains 
Recombinant proteins were expressed in calcium competent E. coli BL21 (DE3) 
Rosetta cells. For routine plasmid cloning, subcloning efficiency NEB 5-alpha calcium 
competent E. coli were used (New England Biolabs). For site-directed mutagenesis, 
either high efficiency NEB 10-beta calcium competent E. coli (New England Biolabs) 
or XL-1 blue supercompetent E. coli (Agilent) were used.  
 
2.7 Bacterial growth media 
For bacterial growth, agar plates were made with lysogeny broth LB media [1% (w/v) 
tryptone, 0.5% (w/v) yeast extract and 0.5% (w/v) NaCl, pH 7.4] supplemented with 
1.5% (w/v) bacto agar (Miller's LB Agar, Melford) and 50 µg/ml of kanamycin for 
selection of resistant colonies. The LB media used as rich liquid growth media was the 
same as described above except bacto agar was not added (LB broth granulated, 
Melford).  
 
For isotopically (15N or 15N/13C) labelled proteins, growth was carried out in M9 
minimal media. To prepare M9 media, firstly M9 salts [Na2HPO4 (6 g/L), KH2PO4 (3 
g/L), NaCl (0.5 g/L)] were sterilised by autoclaving. The M9 salt solution was then 
supplemented with labelled ammonium chloride (>98 % 15N, Sigma-Aldrich) and/or 
glucose (>99% U-13C, Sigma-Aldrich), 0.1 µM CaCl2, 2 µM MgSO4, BME Vitamins 
100x solution (10 ml/L) (Sigma-Aldrich), 10 ml/L trace elements from 10X stock 
solution (10 mM FeCl3·6H2O, 5 mM CuCl2·6H2O, 10 mM ZnCl2·4H2O, 15 mM 
CoCl2·6H2O, 2 mM H3BO3 and 10 mM Na2MoO4·2H2O), and 50 µg/ml of kanamycin. 
All M9 supplements were added as filtered sterilised solutions using syringe driven 
filters with 0.22 µm pores (Millex-GP syringe filter unit, Millipore). 
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2.8 Synthetic peptides  
The human Rpn13 derived pentapeptide (Rpn13 residues 403-407; sequence - DMSLD) 
used in this study was synthesised by Alta BioScience (Birmingham, UK). The purified 
peptide was verified by HPLC and mass spectrometry. 
 
2.9 Chromatography 
Chromatography columns were obtained pre-packed. HisTrap columns (5 ml) 
prepacked with high performance nickel Sepharose were used for purification of 
histidine-tagged proteins by immobilized metal ion affinity chromatography (IMAC). 
Size-exclusion chromatography was carried out on either a 120 ml HiLoad 16/60 
Superdex 200 prep grade column (GE Healthcare), or a 120 ml HiLoad 16/60 Superdex 
75 prep grade column (GE Healthcare). Chromatography was carried out on AKTA 
prime, AKTA purifier or AKTA pure fast protein liquid chromatography (FPLC) 
systems controlled by the Unicorn software package (GE Healthcare).  
 
2.10 Agarose gel electrophoresis 
Agarose gel electrophoresis was carried out on 1% (w/v) agarose gels prepared in 1X 
TAE (Tris-acetate–EDTA) buffer (40 mM Tris-HCl pH 7.6; 20 mM acetic acid; 1mM 
EDTA). 6X DNA loading dye (1X TAE, 5% (w/v) glycerol, 0.04% (w/v) bromophenol 
blue, 0.04% (w/v) xylene cyanol FF) was added to DNA samples prior to loading on 
agarose gels to track the progress of electrophoresis. Gels were run in 1X TAE at 100 
V. DNA was visualized by straining with SYBR safe DNA gel stain (ThermoFisher 
Scientific), followed by illumination with a safe imager blue-light transilluminator 






Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was carried 
out on discontinuous gels (Laemmli, 1970) with a 12% acrylamide resolving gel and a 
5% (w/v) stacking gel. These gels were poured in-house, with the resolving gel 
containing 12% polyacrylamide, 0.45 M Tris-HCl pH 8.8, 1% of SDS, 1% of 
ammonium persulphate and 0.02% of N,N,N,N tetramethylethylendiamine (TEMED). 
On the other hand, the stacking gel was made of 5% of polyacrylamide, 0.125 M Tris-
HCl pH 6.8, 1% of SDS, 1% of ammonium persulphate and 0.02% of TEMED. Protein 
samples were denatured by boiling in SDS loading buffer (50 mM Tris-HCl pH 6.8, 1% 
(w/v) sodium dodecyl sulphate (SDS), 0.01% (w/v) bromophenol blue, 1% β-
mercaptoethanol, 10% (v/v) glycerol), then loaded on to the gels that were run in a 
standard Tris/glycine buffer (Laemmli buffer: 25 mM Tris base, 200 mM glycine and 
1% SDS). Electrophoresis was performed in a Mini-PROTEAN tetra vertical 
electrophoresis cell (Bio-Rad) at a constant current of 42 mA until the dye front had 
reached the end of the gel. Protein bands were visualised by staining with quick 
Coomassie stain (Generon) following the manufacturers instructions. 	  
2.12 Estimation of protein concentration 
Protein concentrations were estimated by measuring sample UV absorbance at a 
wavelength of 280 nm with a NanoDrop 8000 spectrophotometer (Thermo Scientific). 




where, A is measured absorbance, ε is the molar extinction coefficient, c is sample 
concentration, and l is the path length through the sample. Theoretical molar extinction 
coefficients (ε) were obtained from the ExPASy ProtoParm server with amino acid 
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sequence of the protein of interest used as input (http://web.expasy.org/protparam/). For 
protein constructs lacking tyrosine or tryptophan residues concentrations were 
determined using the Pierce BCA assay (Thermo Scientific) calibrated with bovine 
serum albumin following the manufacturer’s protocol. 
 
2.13  Restriction endonuclease mediated cloning  
Expression plasmids encoding full-length human SGTA, full-length human tail-
anchored proteins cytochrome b5 (Cytb5) and synaptobrevin-2 (Syb2), the C-terminal 
domain of human Rpn13, and variants thereof were generated in a home-modified 
pET28 vector (kanamycin resistant). In this system, recombinant mRNA transcription is 
achieved by the IPTG inducible bacteriophage T7 RNA polymerase. All plasmids were 
constructed to encode fusion proteins consisting of an N-terminal thioredoxin (TxA) 
protein followed by a hexa-histidine tag (His6) and rTEV protease cleavage site 
(ENLYFQ	   ^ GS) followed by the sequence encoding the protein of interest. The N-
terminal TxA was engineered to enhance expression levels and improve solubility, the 
His6 was added to aid affinity purification of the resulting protein, and the rTEV site 
was inserted to allow for the removal of this N-terminal part of the fusion protein (Fig. 
2.1). Cloning was carried out in the steps as described below.  
 
2.13.1  Construct design and domain boundaries 
For SGTA constructs, domain boundaries of its N-terminal, TPR and C-terminal 
domains have been defined as follows. The N-terminal region described in the solution 
NMR structure of SGTA (PDB accession code: 4CPG; residues 1-69) (Darby et al., 
2014) together with the flexible linker extending up to the start of the TPR domain was 
designated as the N-terminal domain construct (Nter; residues 1-86). Domain 
boundaries of the central TPR domain were based on the X-ray crystal structure of 
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human SGTA TPR (PDB accession code: 2VYI; residues 84-211) (Dutta and Tan, 
2008). Regions distal to the TPR capping helix were designated as the SGTA C-
terminal domain (residues 213-313). Within this C-terminal domain of SGTA, residues 
213 to 274 constitute the NNP region (short C-terminal), and residues 275 to 313 form 
the Q-rich region, with the definition of both regions based on sequence homology.  
 
For tail-anchored membrane proteins, constructs were designed encoding full-length 
cytochrome b5 (Cytb5; residues 1-134) and full-length synaptobrevin 2 (Syb2; residues 
1-116).  
 
For the intrinsic proteasomal ubiquitin receptor Rpn13, a C-terminal domain construct 
(residues 260-407) encoding its conserved deubiquitinase adaptor (DEUBAD) domain 
followed by a flexible C-terminal extension was designed, based on domain boundaries 
as defined in the solution NMR structure of human Rpn13 (PDB accession code: 2KR0) 
(Chen et al., 2010).  
 
2.13.2  Primer design 
Forward and reverse primers were designed (Table 2.1) in such a way that they 
annealed to the same sequence on opposite strands of the synthetic DNA template 
(Appendix A). This allowed for the amplification of the DNA sequence of interest using 
various combinations of primers (Table 2.2). The forward primer had a BamHI 
restriction site, while the reverse primer contained a XhoI restriction site and a stop 
codon. This was to allow insertion of a restriction-digested fragment into the multiple 











Figure 2.1– Vector map of modified pET28 used for restriction endonuclease 
mediated cloning. A pET28 vector encoding an N-terminally placed thioredoxin A 
(TxA) fusion protein followed by a hexahistidine tag (His6) and rTEV cleavage site was 
used for plasmid cloning. The DNA sequence encoding the gene of interest was 
digested with BamHI and XhoI followed by ligation into a linearised version of this 
















Table 2.1- Primers designed to clone various constructs into a modified pET28 
vector encoding an N-terminal thioredoxin fusion protein followed by a hexa-




SGTA_1_Fw 5’- CGC GGA TCC ATG GAC AAC AAG AAG CGC -3’ 
SGTA_84_Fw 5’- CGC GGA TCC GAG GAG GAC TCA GCA GAG GC -3’ 
SGTA_191_Fw 5’- CGC GGA TCC GAC AAC GAG ACA TAC AAG TCC -3’ 
SGTA_213_Fw 5’- CGC GGA TCC ACG GGA GGC GTG GGC -3’ 
Reverse primers 
SGTA_86_Rv 5’- CGC TCG AGA TCA CTC CTC GGA AGG CGG GG -3’ 
SGTA_211_Rv 5’- CGC TCG AGA TCA CGT GGG GCT GGG GGC C -3’ 
SGTA_240_Rv 5’- CGC TCG AGA TCA ATT GTT CAT TAG GTT CG -3’ 
SGTA_274_Rv 5’- CGC TCG AGA TCA GAT GAG GCT GGC CAG GTC G-3’ 
SGTA_313_Rv 5’- CGC TCG AGA TCA CTC CTG CTG GTC GTC G -3’ 
Tail-anchored proteins Cytochrome b5 (Cytb5) and Synaptobrevin 2 (Syb2) 
Forward primers 
Cytb5_Fw 5’-CGC GGA TCC ATG GCA GAA CAG AGT GAT GAA GC-3’ 
Syb2_Fw 5’-CGC GGA TCC ATG AGC GCA ACC GCA GCC ACC GC-3’ 
Reverse primers 
Cytb5_Rv 5’- CGC TCG AGA TTA ATC TTC TGC CAT ATA C -3’ 
Syb2_Rv 5’- CGC TCG AGA TTA GGT GCT AAA ATA CAC G -3’ 
Rpn13 C-terminal domain constructs 
Forward primer 
Rpn13_260_Fw 
5’- GCC GCG GAT CCC AGC CGA TTC AGC TGA GCG ATC 
TGC -3’ 
Reverse primers 
Rpn13_407_Rv 5’- GGC CGG CTC GAG TTA GTC CAG GCT CAT ATC TTC  
C -3’ 
Rpn13_402_Rv 
5’-GGC CGG CTC GAG TTA TTC CTC TTC GTC TTT TTT 
ATC TTT GG -3’ 
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2.13.3  Polymerase chain reaction 
DNA fragments used for cloning were amplified by PCR using Q5 high-fidelity DNA 
polymerase (New England Biolabs). Typically a mix of 50 µl was prepared per reaction 
containing 0.5 µl polymerase, 10 µl Q5 reaction buffer (5x), 2.5 µl of each primer to 
generate a specific construct (Table 2.2), 2 µl dNTPs, the corresponding DNA template 
(Appendix) and 32 µl of nuclease free water. PCR reactions were performed in a DNA 
Engine Tetrad thermal cycler (Bio Rad) with the following settings: a 30 second 
activation step at 98°C, followed by 30 cycles of denaturation (10 seconds at 98°C), 
annealing of primers (30 seconds at 60°C) and elongation (60 seconds per kilobase at 
72°C). The reaction was ended with a 2 minute step at 72°C. The presence of successful 
amplification products was confirmed by agarose gel electrophoresis.  
 
Table 2.2- Combinations of primers used to amplify various cDNA fragments to 
generate different constructs in the modified pET28 vector. 
SGTA constructs Residues Forward primer Reverse primer 
Full length  1-313 SGTA_1_Fw SGTA_313_Rv 
N-terminal domain 1-86 SGTA_1_Fw SGTA_86_Rv 
N-terminal + TPR domains 1-211 SGTA_1_Fw SGTA_211_Rv 
N-terminal+TPR+short C-terminal 1-274 SGTA_1_Fw SGTA_274_Rv 
TPR domain 84-211 SGTA_84_Fw SGTA_211_Rv 
TPR + C-terminal domains 84-313 SGTA_84_Fw SGTA_313_Rv 
TPR + short C-terminal 84-274 SGTA_84_Fw SGTA_274_Rv 
TPR capping helix + short C-term 191-274 SGTA_191_Fw SGTA_274_Rv 
C-terminal domain 213-313 SGTA_213_Fw SGTA_313_Rv 
Tail-anchored protein constructs    
Cytochrome b5 (Cyt b5) 1-134 Cytb5_Fw Cytb5_Rv 
Synaptobrevin 2 (Syb2) 1-116 Syb2_Fw Syb2_Rv 
Rpn13 constructs    
C-terminal domain 260-407 Rpn13_260_Fw Rpn13_407_Rv 
C-terminal domain (truncated) 260-402 Rpn13_260_Fw Rpn13_402_Rv 
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2.13.4  Purification of DNA fragments 
Purification of DNA obtained by PCR amplification was carried out using the Wizard 
DNA clean-up system (Promega) following the manufacturers instructions. This step 
removed DNA polymerase, primers and dNTPs, with the resulting pure DNA eluted in 
50 µl of nuclease free water.  
 
2.13.5  Restriction digestion 
The modified pET28 vector was linearised by digestion with BamHI (for 5’-end) and 
XhoI (for 3’-end) restriction enzymes (New England Biolabs). Similarly, DNA 
fragments amplified by PCR to be used as inserts were digested with the same 
restriction enzymes. Restriction digestion was carried out at 37°C with 1 µl of each 
enzyme in compatible buffers followed by purification of resulting DNA as described 
above. In addition, the linearised vector was dephosphorylated at its 5’-end using 
shrimp alkaline phosphatase (Roche) for 1 hour at 37°C.  
 
2.13.6  Ligation 
Purified DNA inserts were ligated with linerised plasmids with T7 DNA ligase (New 
England Biolabs). Typically, 0.5 µl of dephosphorylated linearised plasmid (50-100 
ng/µl) was mixed with 6.5 µl of a purified DNA insert with sticky ends, 1 µl T7 DNA 
ligase and 2 µl of T7 ligase buffer. Ligation was carried out overnight at 16°C.  
 
2.13.7  Transformation 
The ligation product from cloning was transformed into NEB 5-alpha calcium 
competent E. coli cells (New England Biolabs). Competent cells were thawed on ice to 
maximise transformation efficiency. 5 µl of the ligation product was added to 50 µl of 
NEB 5-alpha cells and incubated on ice for 30 minutes. This was followed by a heat-
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shock step for 30 seconds at 42°C. Cells were then outgrown at 37°C for 1 hour in 500 
µl SOC media on a shaking platform. The cells were then plated on warm LB-agar 
plates with kanamycin for selection of resistant colonies. These plates were incubated 
overnight at 37°C.  
 
2.13.8  Isolation of plasmid DNA 
Overnight starters cultures were prepared by inoculating LB media (with kanamycin) 
with a single colony obtained from transformation into NEB-5 alpha cells. These cells 
were harvested by centrifugation and used for plasmid DNA extraction. This was 
carried out with the Wizard Plus SV minipreps DNA purification system (Promega) 
following the manufacturers instructions. Pure plasmid DNA was eluted in 30 µl of 
nuclease free water and plasmid sequences were validated by Sanger sequencing using 
the express sequencing service provided by Beckman Coulter Genomics. 
 
2.14 Site-directed mutagenesis 
Different point mutants were generated by site-directed mutagenesis using the 
QuikChange approach (Agilent Technologies). PCR mutagenesis reactions were carried 
out using respective templates and different oligonucleotides carrying the mutated 
codons as primers to generate the desired mutant (Table 2.3). PCR reactions were 
carried out with 0.25 µl Q5 high-fidelity DNA polymerase, 5 µl Q5 reaction buffer (5x), 
1.25 µl of primer (only one primer used), 0.5 µl template, 1 µl dNTPs and made up to a 
total reaction volume of 25 µl with nuclease free water. PCR reactions were performed 
in a DNA Engine Tetrad thermal cycler (Bio Rad) with the following settings: a 30 
second activation step at 95°C, followed by 25 cycles of denaturation (30 seconds at 
95°C), annealing of primers (1 minutes at 55°C) and elongation (68°C for 6 minutes). 
The reaction was ended with a 7 minute step at 68°C. The PCR product was then 
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digested with DpnI for 2 hours at 37°C to remove parental DNA. The DpnI digested 
product was transformed into either high efficiency NEB 10-beta calcium competent E. 
coli (New England Biolabs) or XL-1 blue supercompetent E. coli (Agilent) as described 
above, followed by isolation of plasmid DNA from positive colonies. All mutant 




Table 2.3- Primers designed to generate various point mutants using quick-change 
site directed mutagenesis. 
SGTA TPR  Primer for site-directed mutagenesis  
K160E/R164E 
5’- CCC GGC CTA CAG CGA GGC CTA CGG CGA GAT GGG 
CCT GGC GCT C -3’ 
SGTA C-terminal domain  
S218C 5’- GGA GGC GTG GGC TGC TTC GAC ATC GCC GGC C -3’ 
S232C 5’- GAA CAA CCC TGG CTT CAT GTG CAT GGC TTC G -3’ 
S235C 5’- ATG AGC ATG GCT TGC AAC CTA ATG AAC AAT C -3’ 
S248C 5’- GCA GCT CAT GTG CGG CAT GAT TTC GGG TGG C -3’ 
S252C 5’- ATG TCC GGC ATG ATT TGC GGT GGC AAC AAC C -3’ 
S264C 5’- AAC TCC CGG CAC CTG CCC CTC GCA GAA CGA C -3’ 
S272C 5’- CCC TCG CAG AAC GAC CTG GCC TGC CTC ATC C -3’ 
S297C 5’- GAT AGA GCA GCT CAG GTG CCA GAT CCG GAG T -3’ 
S307C 5’- GGA CGC CCA GCG CCT GCA ACG ACG ACC AGC A -3’ 
A281C 5’- GGG CCA GCA GTT TTG CCA GCA GAT GCA GCA GC -3’ 
Rpn13 C-terminal domain 
K398C 5’- CCA AAG ATA AAT GCG ACG AAG AGG AAG ATA TG -3’ 
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2.15  Heterologous expression and purification of recombinant proteins 
Recombinant human proteins were expressed in E. coli as hexahistidine (His6) tagged 
thioredoxin A (TxA) fusion constructs that were purified by nickel affinity 
chromatography followed by tag and TxA removal. In most cases, size-exclusion 
chromatography (SEC) was used as a polishing step to obtain pure protein. Purification 
of recombinant protein samples was achieved as described in the following steps.  
 
2.15.1  Transformation 
The expression plasmids were transformed into E. coli Rosetta (DE3) competent cells 
(Novagen) by the heat shock method. Calcium competent E. coli cells (50 µl, OD600 = 
0.4) were incubated on ice for 30 min together with an addition of ~100 ng of plasmid 
DNA. The cells were then heat shocked at 42°C for 30 s. Cells were then recovered in 
500 µl SOC outgrown media at 37°C for 1 hour on a shaking platform. The cells were 
subsequently spread onto LB agar plates and incubated overnight at 37°C with 
kanamycin (50 µg/ml) used for selection. 
 
2.15.2  Preparation of overnight pre-cultures 
For unlabelled protein expression, a few colonies arising from the transformations were 
picked and used to inoculate 10 mL LB media with antibiotics, which was then 
incubated at 37°C overnight. This resulting overnight pre-culture was used to inoculate 
1L of LB media with antibiotics.  
 
To prepare isotopically labelled samples, colonies from transformations were used to 
inoculate 50 mL LB media with antibiotics (50 µg/ml), which was then incubated at 
37°C overnight. The cells were harvested by centrifugation (4, 000 × g; 15 min; 4°C) 
then resuspended in 50 mL complete M9 media. The resuspended cells were used to 
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inoculate 1 L of complete M9 media supplemented with either 15NH4Cl, or 15NH4Cl 
together with 13C6H12O6, to express isotopically (15N or 13C/15N) labelled recombinant 
proteins.  
 
To prepare deuterated samples, a few colonies from the transformations were picked 
and used to inoculate 10 mL LB media with antibiotics, which was then incubated at 
37°C overnight. This pre-culture (200 µl) was used to inoculate 50 ml of filter sterilised 
complete M9 media prepared in 100% D2O, which was then incubated at 37°C 
overnight. The cells were harvested by centrifugation and resuspended in 50 mL 
complete M9 media prepared in 100% D2O. These cells were used to inoculate 500 mL 
of complete M9 media prepared in 100% D2O supplemented with either 15NH4Cl, or 
15NH4Cl together with 13C6H12O6 to achieve high levels of deuteration of labelled 
proteins. 
 
2.15.3  Expression of recombinant proteins 
The cells were grown in 1 L cultures at 37°C until their density had reached an 
absorbance of around 0.4 - 0.6 at 600 nm. Protein expression was induced by the 
addition of isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 0.3-
0.5 mM. Post induction, recombinant protein was expressed overnight at 18°C, then 
harvested by centrifugation (5, 000 rpm; 15 min; 4°C) the following day using a JLA-
8.1000 rotor (Beckman Coulter). 
 
2.15.4  Purification of recombinant proteins by nickel affinity chromatography 
All subsequent steps were performed at 4°C. The cells were re-suspended in 50 ml 
buffer A [20 mM potassium phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole, 250 
µM TCEP] with protease inhibitors tablets (complete mini, EDTA-free, Roche) and 1 
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µg/ml DNase I. All buffers were filtered (pore size 0.2 µm, Sartorius Stedim Biotech) 
and cooled to 4°C prior to use. The cells were lysed by cell disruption (Constant 
Systems Ltd.). Cell membranes and insoluble material were removed by centrifugation 
(17000 rpm; 1 h; 4°C) using a JA25.50 rotor (Beckman Coulter). The resulting 
supernatant was filtered through a syringe-driven Millipore express membrane (pore 
size 0.45 µm) and cleared lysate was applied to a 5 ml Hi-Trap nickel affinity column 
(GE Healthcare) pre-equilibrated in buffer A, at a flow rate of 2 ml/min. Recombinant 
protein was eluted with a 300 mM imidazole step using 100% buffer B [20 mM 
potassium phosphate pH 8.0; 300 mM NaCl; 300 mM imidazole; 250 µM TCEP]. The 
nickel column eluate (100% B) was treated with 100 µM PMSF and 0.5 mM EDTA. 
This was followed by the addition of rTEV protease to remove the TxA fusion protein 
and His6 tag. Samples with rTEV were dialysed overnight against 4 L of buffer A using 
Spectra/Por or Spectra/Por4 dialysis membrane (Spectrum Laboratories, Inc.). The 
overnight dialysed sample was then loaded on to a 5 ml Hi-Trap nickel affinity column 
equilibrated in buffer A, and the flow through from this column was collected that 
contained the desired protein devoid of TxA fusion protein and His6 tag (reverse nickel 
chromatography step).  
 
2.15.5  Size-exclusion chromatography (SEC) 
The purest fractions were identified by SDS-PAGE then subjected to centrifugal 
concentration (Vivaspin 20, Sartorius Stedim Biotech) prior to size-exclusion 
chromatography (SEC). SEC was carried out on either a 120 ml HiLoad 16/60 Superdex 
200 prep grade column (GE Healthcare), or a 120 ml HiLoad 16/60 Superdex 75 prep 
grade column (GE Healthcare) pre-equilibrated in gel filtration buffer [10 mM 
potassium phosphate pH 6.0; 100 mM NaCl; 250 µM TCEP] at a flow rate of 1 ml/min. 
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2.15.6  Purification of recombinant tail-anchored proteins 
To purify full length human tail-anchored proteins cytochrome b5 (Cytb5) and 
synaptobrevin 2 (Syb2) cell pellets were resuspended in 50 ml lysis buffer [50 mM 
HEPES pH 7.5; 300 mM NaCl; 10 mM imidazole; 5% glycerol; 1% DDM] with 100 
µM PMSF, 1 µg/ml DNase I, and protease inhibitors tablets (complete mini, EDTA-
free, Roche). The cells were lysed by incubation with 0.2 mg/ml lysozyme for 1 hr at 
room temperature on a rotating platform. Lysate was cleared by centrifugation (17000 
rpm; 1 h; 4°C) using a JA25.50 rotor (Beckman Coulter). The supernatant was filtered 
through Millipore express membrane (pore size 0.45 µm) and applied to a 5 ml nickel 
affinity column equilibrated in TA buffer A [50 mM HEPES pH 7.5; 300 mM NaCl; 10 
mM imidazole; 250 µM TCEP; 0.1% DDM]. Elution of His6-tagged recombinant TA 
proteins with N-terminal TxA fusion protein was carried out by an imidazole step using 
TA buffer B [50 mM HEPES pH 7.5; 300 mM NaCl; 300 mM imidazole; 250 µM 
TCEP; 0.1% DDM]. The TxA fusion protein and His6 tag were removed by overnight 
rTEV digestion. Full-length TA proteins were obtained by reverse nickel 
chromatography as described above, and sample purity was assessed by SDS-PAGE. 
 
2.16 Analytical size-exclusion chromatography 
Analytical size-exclusion chromatography (Analytical SEC) can be used to separate 
proteins based on size. Analytical SEC was performed on either a 25 ml Superdex 200 
10/300 GL column (GE Healthcare) or a 120 ml HiLoad 16/60 Superdex 75 column 
(GE Healthcare) pre-equilibrated with 10mM KPi, 100mM NaCl at pH 6.0. The flow 
rate was maintained at 1 ml/min. Where necessary molecular mass was estimated based 
on the migration of protein standards on the SEC column (aprotinin – 6.5 kDa, 
ribonuclease A – 13.7 kDa, carbonic anhydrase – 29.0 kDa, ovalbumin – 44.0 kDa, 
conalbumin – 75.0 kDa and aldolase – 158.0 kDa; GE Healthcare). 
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2.17  Solution NMR spectroscopy 
Solution NMR spectroscopy is a widely used technique to understand the structure and 
dynamics of proteins in solution. It is routinely used to characterise protein-protein and 
protein-ligand interactions, and to investigate biomolecular motions. In addition, NMR 
spectroscopy can be used to determine atomic resolution structures of small proteins, 
and to probe structures of larger proteins. Furthermore, NMR can be used to probe 
protein structure and interactions within living cells. Also, recent years have seen an 
increase in the use of protein NMR in the discovery of novel therapeutics (Barrett et al., 
2013). 
 
Solution NMR experiments were carried out on Bruker Avance spectrometers operating 
at 400, 500 and 700 MHz at the Centre for Biomolecular Spectroscopy, King’s College 
London. The 500 MHz and 700 MHz spectrometers were equipped with a triple 
resonance (1H/13C/15N) cryoprobe with z-gradients, and a quadruple resonance 
(1H/13C/15N/31P) cryoprobe with z-gradients, respectively. The 400 MHz Bruker Avance 
spectrometer was equipped with a 1H/{13C,19F,31P} QNP probe. Further NMR 
experiments were carried out on the 950 MHz Bruker spectrometer, equipped with a 
cryoprobe at the MRC Biomedical NMR Centre, The Francis Crick Institute, London. 
All NMR experiments were recorded at 25°C. The spectrometers were controlled by 
Topspin version 3.1 (Bruker Biospin Ltd). NMRPipe (Delaglio et al., 1995) and 
CcpNMR Analysis (Skinner et al., 2015; Vranken et al., 2005) were used for spectral 
processing and analysis. A summary of acquisition parameters used in key 1D and 2D 























































































































































































































































































































































































































































































































































































































































































































2.17.1  1D 1H NMR 
Proton 1D NMR shows all observable protein signals in the sample. For proteins, these 
signals are highly overlapped. However, these experiments can still provide information 
on a protein’s degree of structure, or lack thereof. For instance, poor amide dispersion 
together with an absence of ring current shifted methyl signals is indicative of an 
unstructured protein. Conversely, good dispersion of amide signals alongside ring 
current shifted methyl signals can be used as an indication of a structured protein.  
 
2.17.2  2D 1H-15N HSQC experiments 
The 1H-15N HSQC spectrum of a protein can be described as a ‘fingerprint’ of its 
backbone and side chain amide groups. In other words, a cross-peak can be obtained 
from the amide group of every amino acid except proline. As the HSQC is extremely 
sensitive to ligand binding, it is widely used to detect and characterise protein-ligand 
and protein-protein interactions. 15N labelled proteins are used routinely in NMR 
titration experiments to observe changes in the 1H-15N HSQC spectrum of a protein 
upon titration with increasing amounts of unlabelled proteins in order to characterise 
binding, and map resulting binding interfaces. In addition, 3D experiments used for 
sequential backbone assignment of proteins are built upon a 1H-15N HSQC with an 
added dimension corresponding to another nucleus (typically 13C) (Campbell, 2012). 
 
The HSQC experiment was first described by Bodenhausen and Ruben (1980), and is 
based on two INEPT (insensitive nuclei enhanced by polarization transfer) type 
magnetization transfer steps between proton and directly attached heteroatoms (such as 
15N) via a large scalar coupling constant (JH-N = 90-100 Hz) separated by t1 chemical 
shift evolution periods. A series of experiments are recorded each with increments in t1, 
which give rise to the indirect dimension (15N in this case). The 1H signal is acquired as 
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the directly measured dimension of each experiment (Campbell, 2012; Bodenhausen 
and Ruben, 1980). 
 
2.17.3  NMR sample conditions 
Unless stated otherwise, protein samples for solution NMR spectroscopy were dialysed 
into NMR buffer [10 mM potassium phosphate pH 6.0; 100 mM NaCl; 250 µM TCEP] 
by overnight dialysis or gel filtration chromatography. Protein samples at 
concentrations between 200-800 µM were prepared with 10% D2O (Sigma Aldrich) in 5 
mm NMR tubes (VWR International).  
 
2.17.4  NMR titrations 
Proteins used for NMR titrations were dialysed overnight against NMR buffer (10 mM 
potassium phosphate pH 6.0, 100 mM NaCl and 250 µM TCEP) and combined in 
different molar ratios. 1H-15N HSQC experiments were recorded with a 20 min 
acquisition for each titration point. Chemical shift perturbation (CSP) values were 
calculated for each amide signal using the following formula: 
 
∆𝛿!" = ∆𝛿!! ! + ∆𝛿!"! 5 ! · 0.5 
 
where Δδ1H and Δδ15N are the chemical shift differences for the same amide in its free 
and bound state (δfree-δbound) and for proton and nitrogen chemical shift values 
respectively. CSP results were mapped on to crystal structures using the PyMOL 




2.17.5  Triple resonance experiments for sequential backbone assignment 
Sequential backbone assignment of the SGTA C-terminal domain was carried out using 
information pertaining to connectivity between amino acids obtained from the following 
standard triple resonance experiments: HNCO, HN(CA)CO, HN(CO)CA, HNCA, 
CBCA(CO)NH, and CBCANH (Clubb et al., 1992; Grzesiek and Bax, 1992a; Grzesiek 
and Bax, 1992b; Grzesiek and Bax, 1992c). These 3D experiments were carried out on 
13C/15N labeled protein samples. Assignment of backbone amide resonances of the 
SGTA C-terminal domain was carried out by Dr Santiago Martinez-Lumbreras (KCL). 
 
2.17.6  15N NMR relaxation experiments 
15N relaxation experiments are routinely used to characterise molecular motions of 
proteins in solution. These experiments rely on the generation of a non-equilibrium spin 
order, and subsequent observation of how this returns to equilibrium. The relaxation 
parameter T1 describes spins that relax back to equilibrium along the direction of the 
external magnetic field, and thus referred to as the longitudinal relaxation time. When 
the magnetization is ordered perpendicular to the external magnetic field, the relaxation 
time of this spin-order to return back to equilibrium is referred to as the transverse 
relaxation time T2. 15N relaxation experiments can provide information regarding the 
overall correlation time of a protein (calculated from T1 and T2 values) (Wagner, 1995; 
Campbell, 2012). Additionally, there is another relaxation parameter referred to as the 
heteronuclear nuclear Overhauser effect (NOE). This parameter is measured by 
saturating the proton signal and detecting changes in the 15N signal. Heteronuclear NOE 
values provide valuable information regarding the presence of rapid motion due to local 
flexibility, as negative values are indicative of high frequency molecular motions 
(Wagner, 1995).  
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For T1 measurements a series of spectra with 30.8, 61.6, 123.2, 246.4, 369.6, 554.4, 
739.2, 985.5, 1232, 1386 and 1540 ms delays were recorded. On the other hand, spectra 
series with 16.96, 33.92, 50.88, 67.84, 84.8, 118.72, 152.64, 186.56, 220.48 and 254.4 
ms CPMG echo delays were recorded for T2 measurements. T1 and T2 relaxation times 
were calculated from the single exponential decay fitting of peak intensities of each 
amide signal. Rotational correlation times (τc) of various different constructs have been 
calculated from the T1/T2 averaged values using the following equation: 
 𝜏! ≈ 14𝜋𝜐! 6𝑇!𝑇! − 7 
where νN is the spectrometer frequency (Kay et al., 1989). The rotational correlation 
time (τc) is roughly the time it takes for a molecule to rotate by one radian.  
 
In addition, {1H}15N heteronuclear NOE experiments were performed with a four 
second saturation transfer or control period. The {1H}15N heteronuclear NOE values are 
given by: 
{1H}15N heteronuclear NOE=    𝐼𝑠𝑎𝑡𝐼𝑢𝑛𝑠𝑎𝑡 
where Isat and Iunsat are the cross-peak intensities observed during the saturation transfer 
and control periods, respectively (Kay et al., 1989).  
 
2.17.7  PRE experiments 
It is known that the magnetic moment of an unpaired electron is hugely greater (658-
fold) than that of a 1H nucleus (Campbell, 2012). As a result, distance-dependent line 
broadening of NMR signals can be observed in protein spectra in the presence of 
paramagnetic species (Battiste and Wagner, 2000). These paramagnetic relaxation 
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enhancement (PRE) effects can provide information about molecular motions and 
distances between the paramagnetic centre and the observed nucleus. Paramagnetic spin 
labelling of proteins can be achieved by modifying free cysteines with thiol-reactive 
nitroxide spin-labeled compounds, and the resulting PRE effect can be detected over 
distances of around 0 to 25 Å for a proton experiencing relaxation enhancement from a 
nitroxide spin-label (Barrett et al., 2013). 
 
Intermolecular PRE effects were recorded to understand details pertaining to the 
binding interface between Rpn13 and SGTA_TPR. For spin labelling, a C-terminal 
residue of Rpn13 (Lys 398) was mutated to a cysteine, which allowed for the covalent 
attachment of both paramagnetic and diamagnetic probes. The thiol-specific 1-oxyl-
2,2,5,5-tetramethylpyrroline-3- methyl methanethiosulfonate (MTSL) was used as the 
paramagnetic probe, and the structurally similar 1-acetyl-2,2,5,5-tetramethyl-Δ3-
pyrroline-3-methyl methanethiosulfonate (dMTSL) was used as a diamagnetic control. 
Unlabelled mutant Rpn13260-407 was treated with excess TCEP for 2 hours to ensure 
cysteines were reduced, followed by dialysis against 10 mM potassium phosphate pH 
6.0, 100 mM NaCl buffer to remove excess TCEP. Mutant samples were then incubated 
with either diamagnetic (dMTSL) or paramagnetic (MTSL) spin labels (Santa Cruz 
Biotechnology) overnight at 4°C. Excess dMTSL/MTSL was removed by extensive 
dialysis against 10 mM potassium phosphate pH 6.0, 100 mM NaCl. For intermolecular 
PRE experiments, 15N-labelled SGTA_TPR in 10 mM potassium phosphate pH 6.0, 100 
mM NaCl buffer was mixed with each spin labelled Rpn13 sample at a 1:1.2 ratio. A 




Proximity dependent line broadening of 15N-labelled SGTA_TPR backbone amide 
signals was monitored for intermolecular paramagnetic relaxation enhancement (PRE) 
effects upon addition of MTSL labelled K398C Rpn13260-407. This would enable 
mapping of the position of the MTSL spin label within a 25 Å distance of amide signals 
corresponding to SGTA_TPR residues. PRE intensity ratios were calculated as follows: 
 
Intensity ratio = 𝐼𝑝𝑎𝑟𝑎𝐼𝑑𝑖𝑎  
where Ipara and Idia are peak intensities measured in the presence of paramagnetic 
(MTSL) and diamagnetic (dMTSL) probes, respectively.  
 
2.17.8  Fluorine-19 NMR 
Fluorine-19 is a spin-½ isotope and has high sensitivity for observation by NMR, 
corresponding to 83% of 1H sensitivity (Didenko et al., 2013). Thus 1D fluorine-19 
NMR can be used to observe extrinsic 19F labels that have been incorporated into 
protein samples. In addition, fluorine-19 chemical shifts are extremely sensitive to the 
local environment, making 19F labels on proteins suitable probes to detect protein-
protein interactions. Furthermore, in cases where regions on proteins cannot be 
observed by standard NMR methods, fluorine-19 NMR can provide a way to probe such 
regions. 19F probes can be attached to proteins post-translationally, such incorporation 
can be achieved by chemical conjugation of small molecules containing 19F with 
reactive thiol groups on cysteine residues (Horst et al., 2013; Didenko et al., 2013). 
 
Fluorine-19 NMR has been used to investigate the interaction of TA proteins with the 
C-terminal domain of SGTA. Incorporation of 19F containing 3-bromo-1,1,1-
trifluoroacetone (BTFA) (Fig. 2.2) to cysteine residues positioned at different locations 
of the SGTA C-terminal domain was carried out in a single-step process resulting in the 
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formation of a stable thioester bond. All SGTA C-terminal domain cysteine mutants in 
NMR buffer (10 mM potassium phosphate pH 6.0, 100 mM NaCl and 250 µM TCEP) 
were treated with 100 µM BTFA at 4°C overnight, then dialysed extensively against 
NMR buffer to remove traces of free BTFA. For spectra acquisition, 225 µl of the 
BTFA labeled protein sample was prepared in a 5 mm NMR tube. Free BTFA used for 
chemical shift referencing was prepared at 100 µM in D2O in a 3 mm NMR tube, which 
was placed within the 5 mm tube prior to acquisition.  The same 3 mm tube was used as 
reference for all 19F spectra of the different cysteine mutants. 1D 19F spectra were 
recorded at 25°C on a 400 MHz Bruker Avance spectrometer, equipped with a 




Figure 2.2- 3-bromo-1,1,1-trifluoroacetone (BTFA). BTFA was incorporated to 
cysteine residues positioned at different locations of the SGTA C-terminal domain.  
 
2.18 Isothermal titration calorimetry (ITC) 
Isothermal titration calorimetry (ITC) is a technique that can be used to accurately 
determine binding constants and thermodynamic parameters underlying molecular 
interactions. ITC provides a direct measurement of heat generated or absorbed as the 
result of an interaction. This technique is therefore used to obtain the Gibbs free energy 
(ΔG), which can be subsequently decomposed into enthalpy (ΔH) and entropy (ΔS) 
thereby providing a complete picture of the thermodynamic profile associated with a 
binding event (Velazquez-Campoy et al., 2004). Isothermal titration calorimeters 
typically consist of a reference and a sample cell, both contained within a thermal 
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insulation jacket. The reference cell contains water or buffer, while the sample cell 
holds one of the binding partners and a stirring syringe which injects the other binding 
partner. Heat changes are monitored by measuring the differential power required to 
maintain a zero temperature difference (i.e. an isothermal condition) between the 
reference and sample cells, as the binding partners are mixed with each other 
(Campbell, 2012; Velazquez-Campoy et al., 2004).  
 
ITC experiments were performed using an ITC-200 microcalorimeter from Microcal 
(GE Healthcare) at 25°C following the manufacturers protocol. Proteins or peptide 
samples were prepared in 10 mM potassium phosphate pH 6.0, 100 mM NaCl, 250 µM 
TCEP. In each titration, either 40 injections of 1 µL or 20 injections of 2 µL of 
SGTA_TPR each, at a concentration of 1 mM, were added to a sample of Rpn13 or the 
Rpn13 derived DMSLD peptide at a concentration of 50 µM in the sample cell. A 
nonlinear least-squares minimization algorithm was applied to integrated heat data 
obtained for the titrations, corrected for heats of dilution, in order to fit the 
experimentally obtained values to a theoretical titration curve.  This was performed 
using the MicroCal-Origin 7.0 software package. ΔH (reaction enthalpy change in 
kcal/mol), Kb (equilibrium binding constant in per molar), and n (molar ratio between 
the proteins in the complex) were used as fitting parameters. The reaction entropy, ΔS, 
was calculated using the relationships ΔG = −RT lnKb (R = 8.314 J/(mol K), T = 298 K) 
where ΔG = ΔH − TΔS. Dissociation constants (Kd) have been determined for each 
interaction. Binding was assumed to be at one site (n = 1), to determine the binding 






2.19 Circular dichroism spectroscopy 
Circular dichroism (CD) spectroscopy is based on the differential absorption of protein 
samples upon interaction with left- and right- circularly polarized light. This can be 
expressed as  
ΔA= AL – AR = Δεcl 
 
where AL and AR are the absorbances of the left- and right circularly polarized beams, 
respectively, Δε is the differential absorption coefficient, c is sample concentration, and 
l is the path length through the sample. In addition, the differential absorption 
coefficient is given by Δε = εL - εR for left- and right circularly polarized beams. Molar 
ellipticity (θ) is the parameter commonly used to report CD measurements, with θ = 
3298Δε (degree cm2 mol-1). In particular for proteins, mean molar ellipticity per residue 
is reported, which is given by θ divided by the number of amino acids in the protein 
(Campbell, 2012). 
 
For proteins, the spectral region ranging from 170-250 nm is of particular interest as it 
is dominated by the polypeptide backbone. As the peptide bond is one of the main 
chromophores of interest in CD spectroscopy, the 170-250 nm region can be used to 
estimate the secondary structure of proteins. Thus characteristic spectral signatures 
corresponding to protein secondary structural elements can be obtained by CD 
spectroscopy (Campbell, 2012; Greenfield, 2007).  
 
CD spectra of various SGTA constructs were acquired using Aviv circular dichroism 
spectrophotometer, model 410 (Biomedical Inc., Lakewood, NJ, USA). Protein samples 
were adjusted to 0.5 mg/ml  in 10 mM KPi, 100mM NaCl, pH 6.0 buffer and the 
experiments were recorded using a rectangular demountable Suprasil quartz cell of 0.1 
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mm pathlength (Hellma Analytics). Each sample was scanned three times from 260 to 
190 nm, at 1-nm intervals with an averaging time of 0.5 s. After background 
subtraction, data was converted to mean molar ellipticity per residue. 
 
2.20 Native mass spectrometry  
Native mass spectrometry can be used to determine the mass of protein assemblies and 
their complexes, held together by non-covalent interactions. This approach can 
therefore be used to detect several different species in a mixture, such as polydisperse 
samples, and can provide information on the stoichiometry of protein complexes. 
Furthermore, non-dissociative nano-electrospray ionization mass spectrometry (Native 
MS) allows for the study of proteins in neutral aqueous buffers in which their structural 
assembly is preserved (Hilton and Benesch, 2012; van den Heuvel and Heck, 2004).  
 
Native MS of SGTA samples (full-length and C-terminal domain) was carried out by Dr 
Dijana Matak-Vinkovic at the Department of Chemistry, University of Cambridge. 
Experiments were carried out on a Synapt HD mass spectrometer (Waters) modified for 
studying high masses. Protein samples were exchanged into 0.20–0.75 M ammonium 
acetate (pH 7.0) solution using Micro Bio–Spin 6 chromatography columns (Bio Rad) 
and diluted to a final concentration of 5–10 µM before analysis. The volume of 2.5 µL 
of protein solution was electrosprayed from a borosilicate emitter (Thermo Scientific) 
for sampling. Typical conditions were capillary voltage 1.8–2.5 kV, cone voltage 60– 
120 V, collision voltage 10−30 V, with backing pressure 3–4 mbar and source 
temperature of 20 °C. Spectra were calibrated externally using cesium iodide. Data 




2.21 High ambiguity driven protein-protein docking  
The high ambiguity driven docking approach (HADDOCK) makes use of protein-
protein interaction data obtained from NMR experiments and/or mutagenesis studies, to 
generate models of protein complexes. In this approach, information on the interacting 
residues within a complex is introduced as ambiguous interaction restraints (AIRs), 
which in turn drives the docking. Then the structures are ranked according to their 
intermolecular energy, which is given by the sum of electrostatic, van der Waals, and 
AIR energy terms (Dominguez et al., 2003). A HADDOCK approach has been adopted 
to obtain a protein-peptide complex of the SGTA_TPR domain with the human Rpn13 
derived DMSLD peptide based on experimental restraints derived from NMR CSP 
studies combined with mutagenesis experiments.  
 
The PDB-deposited structure of SGTA_TPR (accession code 2VYI) and the coordinates 
of the DMSLD pentapeptide from the solution NMR structure of Rpn13 (accession code 
2KR0) were used for the protein-peptide complex structure calculation. Ambiguous 
interaction restraints (AIRs) were implemented using the standard HADDOCK protocol 
(van Zundert et al., 2016; Dominguez et al., 2003). CSP experiments were used to 
identify 10 amino acid residues in SGTA_TPR and 3 within the DMSLD peptide with 
chemical shift changes greater than 0.10 ppm. The Naccess program was used to 
determine relative solvent accessibility, and residues with higher that 45% values were 
identified as active (Hubbard and Thornton, 1993). Based on this approach, 10 residues 
in SGTA_TPR and 3 in the DMSLD peptide, were identified as active. These were 
SGTA_TPR residues 99, 102, 107, 130, 133, 161, 163, 168, 171, 198 and Rpn13 
residues 405, 406 and 407 (for the DMSLD peptide). Solvent exposed residues 
juxtaposed to active residues were automatically designated as passive residues. Rigid 
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body energy minimization was used to generate one thousand initial complex structures, 
from which the best 200 (lowest total energy) were selected for torsion angle and 
Cartesian dynamics in an explicit water solvent. Default scaling was applied for energy 
terms. Following the standard protocol, cluster analysis generated 130 structures in 11 
cluster ensembles. The top-scoring cluster (lowest energy) was considered as the most 
reliable result as determined by HADDOCK benchmark testing (van Zundert et al., 





















Structural and biophysical studies of SGTA carried out thus far have been limited to 
its excised N-terminal (Darby et al., 2014) and TPR domains (Dutta and Tan, 2008), 
with molecular details pertaining to its crucial substrate binding C-terminal domain 
yet to be elucidated. Furthermore, structural and dynamic properties of SGTA in the 
context of its full-length assembly are yet to be understood. This chapter presents a 
detailed biophysical characterisation of full-length SGTA using solution NMR 
spectroscopy, circular dichroism (CD) spectroscopy and non dissociative nano-
electrospray ionization mass spectrometry (Native MS), with an aim to understand 
SGTA assembly in vitro. 
 
3.1. Expression and purification of SGTA constructs 
To glean insights into the domain organisation and conformations of SGTA in vitro, in 
particular within the context of its full-length assembly, various SGTA constructs have 
been designed, encoding individual SGTA domains and combinations thereof (Fig. 3.1). 
Constructs were designed based on sequence homology, and include the extensively 
characterised N-terminal and TPR domains, followed by the C-terminal domain. The C-
terminal domain can be further divided into conserved NNP and Q-rich regions (Fig 
3.1).  
 
SGTA constructs were recombinantly expressed in E. coli Rosetta cells as fusion 
proteins with N-terminally placed thioredoxin A (TxA) followed by a hexa-histidine 
(His6) tag and a rTEV cleavage site. These SGTA fusion proteins were overexpressed at 
18°C overnight, and were all recovered in the soluble fraction (Fig. 3.2), allowing for 











































































































































































Figure 3.2- Recombinant expression of the human SGTA constructs in E. coli. 
SDS-PAGE showing soluble fractions of overexpressed SGTA constructs. Various 
SGTA constructs including excised individual domains and combinations thereof were 
expressed in E. coli Rosetta cells as a fusion protein with an N-terminally placed 
thioredoxin A followed by a hexahistidine tag and rTEV cleavage site. All constructs 










Figure 3.3- Purification of the N-terminal domain of SGTA. SDS-PAGE fractions of 
samples from different stages of Ni-affinity chromatography. Ni- column 1 was used to 
purify the SGTA construct as a fusion protein with TxA. After subsequent TxA and 
His6 tag removal using rTEV, the N-terminal domain of SGTA was recovered in the 
flow-through of Ni- column 2. This purification strategy was used for all other SGTA 







Figure 3.4- Purification of SGTA constructs. SDS-PAGE fractions of samples from 
different stages of Ni-affinity chromatography of (A) full-length (B) the TPR domain, 
and (C) the C-terminal domain of SGTA. All constructs were purified using a similar 
strategy as described for the N-terminal domain.  
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3.2. Analytical SEC of SGTA constructs 
Different SGTA constructs were subjected to analytical size-exclusion chromatography 
(SEC) on a 25 ml Superdex 200 10/300 GL column at a flow rate of 1 ml/min. An 
overlay of the elution profiles of these constructs carried out under identical conditions 
(Fig. 3.5), reveal that constructs including the C-terminal domain of SGTA (FL and 
TPR-Cter) appear at lower elution volumes than expected, based on their size and 
oligomeric state. This is particularly evident with the TPR-Cter construct (residues 84-
313; 25 kDa) that lacks the N-terminal dimerisation domain of SGTA, as it appears at 
an identical elution volume (~14 ml) to the Nter-TPR construct (residues 1-211; 47.2 
kDa) that is known to form a dimer via its N-terminal domain (Fig. 3.5). In comparison, 
both Nter and TPR constructs migrate on the SEC column in a manner indicative of 
their presence as lower molecular weight species (Fig. 3.5). The isolated C-terminal 
domain was not suitable for comparison by this method due to a complete lack of 
aromatic residues. Therefore, based on analytical SEC, the presence of the C-terminal 
domain in SGTA constructs appears to increase the rate of migration of these constructs 
on the SEC column, resulting in a shift towards lower peak elution volumes, indicative 
of the formation of species corresponding to higher molecular weights. 
 
3.3. Circular dichroism spectroscopy of SGTA constructs 
Circular dichroism (CD) spectroscopy on all three isolated domains of SGTA presented 
spectra typical of alpha helical proteins with characteristic minimum ellipticity at 208 
and 225 nm, and maximum ellipticity at around 190 nm (Fig. 3.6). These findings are in 
agreement with the solved structures of the N-terminal and TPR domains which are 
both predominantly alpha helical (Darby et al., 2014; Dutta and Tan, 2008). 
Interestingly, with regard to the C-terminal domain of SGTA these results suggest, for 
the first time, the presence of a certain degree of α-helical propensity within this region 






Figure 3.5- Analytical size-exclusion chromatography (SEC) profiles of SGTA 
constructs. Overlay of SEC chromatograms of different SGTA constructs recorded 
using a 25 ml Superdex 200 10/300 GL column at a flow rate of 1 ml/min. Due to a lack 
of aromatic residues the C-terminal domain construct was not used for comparison 
(extinction coefficient: 0). Molecular mass was estimated based on the migration of 
protein standards on the SEC column (aprotinin – 6.5 kDa, ribonuclease A – 13.7 kDa, 
carbonic anhydrase – 29.0 kDa, ovalbumin – 44.0 kDa, conalbumin – 75.0 kDa and 








Figure 3.6- Circular dichroism (CD) spectra of isolated (A) N-terminal, (B) TPR 
and (C) C-terminal domains of SGTA. CD spectra show that all constructs present α-






















   


































   































   















3.4. Characterisation of SGTA constructs by solution NMR spectroscopy 
 
1D 1H NMR spectra of Nter, TPR, and Nter-TPR constructs (Fig. 3.4) demonstrate 
spectral features typical for folded proteins, which include ring current shifted methyl 
signals (typically between 1 and -1 ppm) and dispersion of amide signals (typically 
higher than 9 ppm). This data is in agreement with with previously determined high 
resolution structures of these domains (Darby et al., 2014; Dutta and Tan, 2008). On 
the other hand, the 1D 1H NMR spectrum of the C-terminal domain construct presents 
poor dispersion of amide signals, together with an almost complete lack of ring current 
shifted methyl signals (Fig. 3.7). This finding indicates the possibility that the C-
terminal domain of SGTA consists of unstructured regions. 
 
To understand the arrangement of individual domains within the context of full-length 
SGTA, a series of comparisons were carried out involving 1H-15N HSQC spectra of 
individual isolated SGTA domains compared to the 1H-15N HSQC of full length SGTA.  
The 1H-15N HSQC of full-length SGTA displayed considerable peak broadening (Fig. 
3.8A), thus sample deuteration was carried out which subsequently led to a marked 
improvement in spectral quality (Fig. 3.8B). When the 1H-15N HSQC spectra of the 
isolated N-terminal and TPR domains were compared to that of the full-length protein 
(Fig. 3.9), it became evident that the fold of each of these isolated domains was 
conserved in the context of full-length SGTA. Similarly, for the C-terminal domain, 
sample deuteration was necessary to circumvent the peak broadening effect (Fig. 3.10), 
possibly arising due to the presence of a Q-rich region, which is likely to have a 
tendency to aggregate in solution. Furthermore, a comparison of the 1H-15N HSQC of 
the C-terminal domain to that of full-length SGTA showed that the C-terminal domain 
is independent of both N-terminal and TPR domains (Fig. 3.11). Also, when the extent 
of amide signal perturbation of residues from each isolated domain was compared to 
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equivalent signals present in the 1H-15N HSQC of full-length SGTA (Fig. 3.12), it was 
clear that except in boundary regions between domains, the local environment 
experienced by amides in each of the isolated domains was the same when compared to 
their presence in full-length SGTA. These finding suggests that the N-terminal, TPR 
and C-terminal domains of SGTA are structurally independent modules. In addition, 
this analysis has shown that inter-domain contacts do not exist in full-length SGTA 
assemblies.  
 
In order to carry out the aforementioned analysis, and subsequent ones described in this 
chapter, assignments of backbone amide resonances of N-terminal and TPR domains 
were obtained from the biological magnetic resonance data bank (BMRB) [BMRB 
accession numbers 19779 (Nter) and 5709 (TPR)]. In addition, standard triple resonance 
experiments were recorded to obtain the assignments of the SGTA C-terminal domain. 
Backbone assignments of the missing regions were carried out by Dr Santiago 
Martinez-Lumbreras (Appendix C). However, due to a complete absence of backbone 
amide signals 50% of residues within the C-terminal domain could not be assigned. In 
total, 84% of backbone assignments could be obtained for full-length SGTA.  
 
Using available chemical shift data, the propensity of secondary structure of each 
domain (CSI) was obtained. As expected, these results show that the N-terminal domain 
is formed of four α-helices and the TPR domain is formed of seven α-helices, with the 
two domains separated by an unfolded linker (Fig 3.13). Almost all observable amino 
acid residues of the C-terminal domain present random coil chemical shift values (Fig. 
3.13). This leads to the possibility that regions within the C-terminal domain that lack 
NMR signals (approximately 50% of C-terminal residues) could have alpha-helical 






































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.11- The C-terminal domain of SGTA is independent of both its N-
terminal and TPR domains. 1H-15N HSQC spectra of deuterated full-length SGTA 
(acquired at 950 MHz) overlaid with 1H-15N HSQC of the deuterated C-terminal 
domain construct (acquired at 700 MHz). Observable amide signals of the excised C-
terminal domain almost completely overlap with equivalent signals in the 1H-15N HSQC 
spectra of full-length SGTA, indicative of its presence as a structurally independent 


































































































































































































































































































3.5. Solution dynamics of SGTA domains  
To investigate the dynamic properties of SGTA in solution, a series of 15N NMR 
relaxation experiments were carried out on full-length SGTA and on isolated domains 
thereof. Firstly, 1H-15N heteronuclear NOE experiments were carried out on four 
constructs (full-length, Nter-TPR, Nter and TPR) to address the motion of NH vectors 
thereby identifying structured domains and unstructured regions within these constructs. 
Naturally, the N-terminal and TPR domains appeared as folded domains in all 
constructs in which they are present, and are separated by flexible linkers in Nter-TPR 
and full-length constructs (Fig 3.14). The 1H-15N NOE values corresponding to 
observable C-terminal residues are typical of flexible proteins, in particular those 
corresponding to extreme C-terminal residues (Fig. 3.14). In addition, NMR relaxation 
parameters of N-terminal and TPR domains have been determined in the context of 
different SGTA constructs (Figs. 3.15 – 3.18). T1 and T2 values and correlation times 
(τc) have been calculated for the N-terminal domain in the context of Nter, Nter-TPR 
and full-length constructs. Similarly, T1 and T2 values and correlation times (τc) were 
computed for the TPR domain in the context of TPR, Nter-TPR and full-length 
constructs. These experiments reveal that the N-terminal domain has similar correlation 
times (~10-11 ns) when present in the context of all three constructs, namely Nter, Nter-
TPR and full-length (Fig. 3.19A). On the other hand, TPR domain correlation times 
appeared to be similar in the context of Nter-TPR and TPR constructs (~9-10 ns). 
Intriguingly, the correlation time of the TPR domain increases to ~12 ns when it is 
present in the context of full-length SGTA (Figs. 3.15 and 3.19B). Therefore, it is 
evident that dynamic parameters of the TPR domain as determined by NMR, are highly 
affected in full-length SGTA, when compared to the other TPR domain containing 
constructs (Fig. 3.19). This suggests that within full-length SGTA, the C-terminal 
domain imposes a viscous drag on the TPR domain, whilst not having an equivalent 
































































































































































































































































































































































































































































































































































Figure 3.15- T1, T2 and T1/T2 values of the full-length construct (acquired at 950 
MHz) plotted as a function of SGTA residue number. T1 and T2 relaxation times 
were calculated from single exponential decay fitting of peak intensities of each amide 
signal. Rotational correlation times of the N-terminal domain within the context of full-
length SGTA were calculated using T1 and T2 values obtained from N-terminal residues 
5 to 65 (indicated by dotted lines). Based on an average T1 = 1341.99 ms, and an 
average T2 = 56.27 ms, an Nter τc = 9.6 ± 2.3 ns was obtained. When based on an 
average Nter T1/T2 value of 24.10, an Nter τc = 9.7 ± 1.7 ns was obtained. In addition, 
rotational correlation times of the TPR domain within the context of full-length SGTA 
were calculated using TPR domain residues 92 to 205 (indicated by dotted lines). Based 
on an average T1 = 1603.39 ms, and an average T2 = 47.12 ms, a TPR τc = 11.6 ± 4.5 ns 































































































































































































































































































































































Figure 3.16- T1, T2 and T1/T2 values of the Nter-TPR construct construct (acquired 
at 700 MHz) plotted as a function of SGTA residue number. T1 and T2 relaxation 
times were calculated from single exponential decay fitting of peak intensities of each 
amide signal. Rotational correlation times of the N-terminal domain within the context 
of the Nter-TPR construct were calculated using T1 and T2 values obtained from N-
terminal residues 5 to 65 (indicated by dotted lines). Based on an average T1 = 1008.62 
ms, and an average T2 = 72.70 ms, an Nter τc = 9.8 ± 1.7 ns was obtained. When based 
on an average Nter T1/T2 value of 14.14, an Nter τc = 9.9 ± 1.6 ns was obtained. In 
addition, rotational correlation times of the TPR domain present within the context of 
the Nter-TPR construct were calculated using TPR domain residues 87 to 205 
(indicated by dotted lines). Based on an average T1 = 991.72 ms, and an average T2 = 
71.94 ms, a TPR τc = 9.8 ± 1.6 ns was obtained. When based on an average TPR T1/T2 

























































































































































































































































































































































Figure 3.17- T1, T2 and T1/T2 values of the isolated Nter domain construct 
(acquired at 500 MHz) plotted as a function of SGTA residue number. Rotational 
correlation times of the N-terminal domain construct were calculated using T1 and T2 
values obtained from N-terminal residues 5 to 65 (indicated by dotted lines). Based on 
an average T1 = 662.03 ms, and an average T2 = 72.54 ms, an Nter τc = 10.9 ± 1.1 ns 
was obtained. When based on an average Nter T1/T2 value of 9.17, an Nter τc = 10.9 ±	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Figure 3.18- T1, T2 and T1/T2 values of the excised TPR domain construct 
(acquired at 700 MHz) plotted as a function of SGTA residue number. Rotational 
correlation times of the TPR domain construct were calculated using TPR domain 
residues 87 to 205 (indicated by dotted lines). Based on an average T1 = 888.06 ms, and 
an average T2 = 76.88 ms, a TPR τc = 8.9 ± 1.4 ns was obtained. When based on an 




















































































































































































































































































































Figure 3.19- Dynamic parameters of the TPR domain are highly affected in full-
length SGTA. (A) Calculated correlations times (τc) for the N-terminal domain in the 
context of Nter, Nter-TPR and full-length constructs. (B) Calculated correlations times 
(τc) for the TPR domain in the context of TPR, Nter-TPR and full-length constructs. 
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3.6 Native mass spectrometry of SGTA constructs 
 
To investigate possible scenarios that could explain the aforementioned viscous drag 
experienced by the TPR domain in full-length SGTA, but not in constructs devoid of 
the C-terminal domain, as observed by NMR relaxation experiments, non dissociative 
nano-electrospray ionization mass spectrometry (Native MS) has been carried out. As 
Native MS can be used to monitor intact proteins and provide information about their 
stoichiometry, full-length and C-terminal domain samples were subjected to this 
technique.  
 
Native MS experiments were carried out by Dr Dijana Matak-Vinkovic at the 
Department of Chemistry, University of Cambridge. As expected, full-length SGTA 
presented dimeric forms as the major species detected (Fig. 3.20A). Interestingly, the 
isolated C-terminal domain construct also exhibited a dimer as the major species (Fig. 
3.20B). This provides a possible explanation for the highly affected dynamic parameters 
of the TPR domain in full-length SGTA. These results have shown, for the first time, 
that SGTA is able to dimerise via its C-terminal domain. These findings are also in 
agreement with analytical SEC experiments (Fig. 3.5) which have suggested that the 
presence of the C-terminal domain within a construct results in the formation of higher 
molecular weight species.  
 
Upon further analysis of these datasets, it was apparent that different forms of the C-
terminal dimer, varying in molecular weight by multiples of 359 ±	  23 Da, were present. 
Mass spectrometry under denaturing conditions has discounted the possibility of these 
adducts arising as a result of covalent modifications of the protein. Therefore, these 
larger species most likely correspond to a non-covalently bound molecule present at a 
stoichiometry of between one and four times that of the SGTA C-terminal domain 
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construct. Curiously, these larger species are only observed in the dimeric form of the 
SGTA C-terminal domain and also appear in the spectrum of full-length SGTA (370 ±	  
15 Da). None of the buffer components correlate with this mass, hence this compound 
most likely corresponds to a lipid, or some other hydrophobic molecule present in the  






Figure 3.20- Non dissociative nano-electrospray ionization mass spectra (Native 
MS) of SGTA samples. (A) Full-length SGTA (B) C-terminal domain of SGTA. 
Molecular weights of each species detected in these samples are indicated. Samples 
were exchanged into 0.20–0.75 M ammonium acetate (pH 7.0) and were present at a 
final concentration of 5–10 µM prior to analysis. 2.5 µL of protein solution was 
electrosprayed from a borosilicate emitter for sampling. Native MS experiments were 
carried out at a capillary voltage of 1.8–2.5 kV, cone voltage of 60– 120 V, collision 
voltage of 10−30 V, with backing pressure 3–4 mbar and source temperature of 20 °C. 
Spectra were calibrated externally using cesium iodide. Data acquisition and processing 







These biophysical experiments provide some novel insights pertaining to the structure 
and assembly of full-length SGTA in vitro. Firstly, CD spectroscopy has indicated the 
presence of alpha helical secondary structural elements within the C-terminal substrate-
binding domain of SGTA. Secondly, characterisation of SGTA constructs by solution 
NMR spectroscopy has revealed that its N-terminal, TPR and C-terminal domains are 
structurally independent modules. Also, the same experiments have confirmed the 
absence of inter-domain contacts in full-length SGTA. In addition, native MS 
experiments have shown, for the first time, the ability of SGTA to dimerise via its C-
terminal region. Finally, a combination of techniques, namely analytical SEC, 15N NMR 
relaxation experiments, and native MS, suggest the presence of a constrained 
conformation of full-length SGTA in vitro. In this proposed conformation, C-terminal 
domains interact with each other closing the dimer at its distal end, thereby constraining 
the mobility of the central TPR domain. These new findings are likely to have 






















Investigation of the interaction 





SGTA is known to interact with hydrophobic substrates via its C-terminal domain (Liou 
and Wang, 2005; Roberts et al., 2015), however molecular level characterisation of this 
process remains scarce. The C-terminal domain of SGTA can be divided into two 
regions namely an NNP region (residues 213-274), and an extreme C-terminal Q-rich 
region (residues 275-313) (Fig. 4.1A). The NNP motifs within the C-terminal region of 
SGTA are conserved across eukaryotes, with human SGTA containing three such 
motifs, thus potentially contributing to SGTA’s hydrophobic substrate binding 
functionality. Also, the presence of glutamine residues is also a conserved feature of the 
C-terminal domain, with possible functional implications. In this chapter I aim to 
understand the role of the SGTA C-terminal domain with respect to its association with 
hydrophobic substrates.  
 
4.1. Expression and purification of SGTA and TA protein constructs for 
interaction studies  
Hence to investigate the interaction between SGTA and its hydrophobic substrates, 
firstly a construct encoding the TPR domain of SGTA followed by its C-terminal NNP 
region (residues 84-274; hereafter referred to as TPR_NNP) was designed to understand 
the contribution of conserved NNP motifs within the C-terminal region of SGTA (Fig. 
4.1A). Furthermore, this TPR_NNP construct would be suitable to understand any 
contributions of the TPR capping helix (helix-7) arising from its proximity to the C-
terminal domain. As tail-anchored membrane proteins are validated substrates of 
SGTA, the full-length TA proteins cytochrome b5 (Cytb5) and synaptobrevin 2 (Syb2) 
were used as hydrophobic substrates in this study. Both Cytb5 and Syb2 comprise a C-





Figure 4.1- SGTA and TA protein constructs designed to understand the shielding 
of hydrophobic substrates by SGTA. (A) Schematics of SGTA constructs 
incorporating regions of its C-terminal substrate binding domain. The TPR_NNP 
construct encodes the central TPR domain of SGTA along with the conserved region of 
the C-terminal domain consisting of three NNP motifs. This construct lacks the C-
terminal Q-rich region.  The C-term construct encodes the entire C-terminal domain of 
SGTA that consists of an NNP region and an extreme C-terminal Q-rich region. (B) 
Schematics of tail-anchored (TA) protein constructs. Both human cytochrome b5 
(Cytb5) and synaptobrevin 2 (Syb2) are TA proteins consisting of a functional cytosolic 
domain (soluble domain) that is tethered to the cell membrane by an extreme C-terminal 
hydrophobic TMD helix. 
 
All protein constructs were successfully cloned, overexpressed in E. coli, and purified, 
as described in Chapter 2 (Materials and Methods) as fusion proteins with N-terminally 
placed thioredoxin A, which improved recombinant protein expression and solubility, 
followed by a hexahistidine tag and a rTEV cleavage site. Furthermore, all proteins 
were recovered in the soluble fraction, and maintained their solubility after removal of 






Figure 4.2- Purification of the TPR_NNP construct. (A) Schematic of the TPR_NNP 
construct. (B) SDS-PAGE showing different stages of TPR_NNP purification.  
TPR_NNP was overexpressed as a fusion protein with thioredoxin A (TxA), purified by 
nickel affinity chromatography and was recovered in the eluate of the first nickel 
column (SDS-PAGE: TxA_His6 + TPR_NNP). This was followed by affinity tag and 
fusion protein removal by treatment with rTEV (SDS-PAGE fraction: +rTEV). Pure 
protein was obtained by passing the rTEV treated fraction through a second nickel 
column with pure protein obtained in the flow-through (SDS-PAGE: TPR_NNP). 
Separated thioredoxin A and rTEV was eluted from the second nickel column (SDS-










Figure 4.3– Purification of tail-anchored (TA) membrane proteins. SDS-PAGE gel 
showing different stages of TA-protein purification. Both Cytochrome b5 (Cytb5) and 
Synaptobrevin 2 (Syb2) were expressed as TxA fusion proteins and purified by Ni-
affinity chromatography. rTEV protease was used to remove affinity tag and TxA 
protein yielding pure TA-proteins (indicated by arrows) obtained from the flow through 
of the second nickel column used in the purification. 
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4.2. Investigation of the interaction between SGTA and hydrophobic 
substrates using standard NMR methods 
Using the abovementioned TPR_NNP construct, 1H-15N HSQC experiments were 
carried out, first to identify backbone amide signals that correspond to C-terminal 
residues of SGTA. An overlay of 1H-15N HSQC spectra of TPR_NNP with that of the 
TPR domain of SGTA (SGTA_TPR) is shown in Fig 4.4. This comparison reveals 
backbone amide signals corresponding to C-terminal residues of SGTA. These 
backbone amide signals were assigned by Dr Santiago Martinez-Lumbreras using 
standard triple resonance experiments. Subsequently, using this information, titrations 
were carried out by adding unlabelled TA proteins to the 15N TPR_NNP construct (Figs. 
4.5-4.7). Titrations with TA proteins cytochrome b5 (Cytb5) (Fig. 4.5) and 
synaptobrevin 2 (Syb2) (Fig. 4.6) were both very similar, with chemical shift 
perturbations observed in backbone amide signals corresponding to some residues 
present in the TPR capping helix (residues 205-210) along with certain observable C-
terminal residues (Figs. 4.7 - 4.9). This revealed some detail with respect to the binding 
of hydrophobic substrates, describing a direct interaction of such substrates with SGTA 
regions distal to the TPR capping helix encompassing the NNP region of the C-terminal 
domain. 
 
However, in 1H-15N HSQC spectra of both C-terminal domain constructs, namely 
TPR_NNP and C-term, peak absence has lead to incompleteness in observable amide 
signals corresponding to regions within the C-terminal domain. In total, 20 residues in 
the NNP region and 30 residues in the Q-rich region of the C-terminal domain could not 
be assigned (Chapter 3). Thus, a complete picture of substrate binding could not be 
gleaned from NMR titrations using 1H-15N HSQC spectra of SGTA constructs that 






Figure 4.4- Identification of backbone amide signals corresponding to C-terminal 
residues of SGTA from the 1H-15N HSQC of the TPR_NNP construct. Overlay of 
1H-15N HSQC of the SGTA_TPR_NNP construct (residues 84-274; in black) with the 
1H-15N HSQC of SGTA_TPR (residues 84-211; in orange), allowing for identification 
of amide signals that belong to the C-terminal domain (labelled). Spectra were acquired 










Figure 4.5– SGTA interacts with cytochrome b5 (Cytb5). 1H-15N HSQC of the 
TPR_NNP construct at 150 µM (in black), overlaid with the 1H-15N HSQC of the 
TPR_NNP construct in the presence of full-length unlabelled cytochrome b5 (in green) 
at a 1:1.5 molar ratio. Spectra were acquired on a 500 MHz spectrometer at 25°C. 
Residues for which changes in amide signals are observed upon association with Cytb5 













Figure 4.6– SGTA interacts with synaptobrevin 2 (Syb2). 1H-15N HSQC of the 
TPR_NNP construct at 150 µM (in black), overlaid with the 1H-15N HSQC of the 
TPR_NNP construct in the presence of full-length unlabelled Syb2 (in light green) at a 
1:1.5 molar ratio. Spectra were acquired on a 500 MHz spectrometer at 25°C. Residues 












Figure 4.7- Hydrophobic substrates interact with residues in the C-terminal 
domain of SGTA. Region of the 1H-15N HSQC of the TPR_NNP construct showing 
perturbation of backbone amide signals corresponding to the C-terminal residues of 
SGTA upon titration with increasing amounts of Cytb5 with the final titration point 













































































































































































































































































































4.3. Design and preparation of SGTA C-terminal cysteine mutants for 19F NMR 
As regions of interest within the C-terminal domain could not be observed by standard 
NMR methods, a 19F NMR based approach was adopted to observe extrinsic 19F labels 
incorporated into the C-terminal domain via thiol groups on cysteine residues. The C-
terminal domain of wild-type SGTA has no cysteine residues. Therefore, SGTA C-
terminal domain cysteine mutants were designed, each carrying a single cysteine point 
mutation, such that the fluorine probes would be present flanking the NNP motifs, and 
the Q-rich region, in order to understand contributions of these regions to substrate 
binding. In addition, a cysteine mutant was introduced at the centre of the Q–rich region 
to further understand its role in shielding hydrophobic substrates. In all but one case, 




Figure 4.10- Schematic of SGTA C-terminal domain showing positions of cysteine 
mutants generated to facilitate the post translational incorporation of fluorine 
probes (BTFA). SGTA C-terminal domain cysteine mutants have been designed such 
that fluorine probes could be incorporated flanking the conserved NNP motifs, and the 
Q-rich region, in order to understand contributions of these regions to hydrophobic 
substrate binding.  
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All SGTA C-terminal domain cysteine mutants were successfully overexpressed and 
purified in an identical manner as described previously for SGTA constructs (Fig. 4.11). 
This was followed by the incorporation of 3-bromo-1,1,1-trifluoroacetone (BTFA), used 





Figure 4.11- Preparation of SGTA C-terminal domain cysteine mutants. SDS-
PAGE gel showing different stages in the purification of SGTA C-terminal domain 
cysteine mutants. A total of ten individual point mutants were purified (Fig. 4.9) in a 
manner identical to the purification of wild-type SGTA. This SDS-PAGE gel shows the 
preparation of three such cysteine mutants. 
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4.4. 19F NMR of SGTA C-terminal domain cysteine mutants 
Each BTFA incorporated C-terminal cysteine mutant was then subjected to 19F NMR, 
with 1D spectra of each BTFA incorporated cysteine mutant acquired at 400 MHz. Free 
BTFA, used for chemical shift referencing, was prepared at 100 µM in D2O in a 3 mm 
NMR tube, which was then placed within the 5 mm tube containing the BTFA 
incorporated cysteine mutant prior to acquisition. Using this technique, it was possible 
to obtain 1D 19F NMR signals that correspond to each BTFA incorporated cysteine 
mutant. These include signals flanking each of the NNP motifs, namely NNP1 (from 
S218C and S232C; Fig. 4.12), NNP2 (from S235C and S248C; Fig. 4.13) and NNP3 
(from S252C and S264C; Fig. 4.14). Also, with respect to the Q-rich region, all four 
signals could be observed (S272C, A281C, S297C and S307C; Fig. 4.15). Interestingly, 
19F NMR signals arising from mutants present within close proximity to the C-terminal 
domain boundaries (S218C and S307C) appear as intense narrow resonances, indicative 
of an unfolded state. This is in agreement with the random coil-chemical shifts that have 
been observed for these regions (Fig. 3.13). On the other hand, 19F NMR signals from 
S252C and S264C flanking the NNP3 motif, and those from S272C and A281C within 
the Q-rich region appear to have undergone considerable peak broadening. This effect 
could possibly be attributed to the fact that these residues, or regions in the vicinity 
thereof, may be undergoing chemical exchange between different states. Additionally, 
due to the extremely sensitive nature of 19F chemical shifts to changes in local 
environment, the abovementioned 19F NMR signals provide us with means to 
understand the somewhat elusive C-terminal domain, regions of which have thus far 
been intractable to analysis by standard NMR methods. In particular, perturbations of 
these signals can be monitored upon addition of substrate to gain insight into the nature 






Figure 4.12- 1D 19F fluorine spectra of SGTA C-terminal domain cysteine mutants 
with BTFA conjugated at positions 218 and 232 flanking the NNP1 motif. Free 
BTFA was used for chemical shift referencing, and peaks arising from free BTFA are 
indicated by blue arrows. Spectra were acquired on a 400 MHz spectrometer at 25°C. 





Figure 4.13- 1D 19F fluorine spectra of SGTA C-terminal domain cysteine mutants 
with BTFA conjugated at positions 235 and 248 flanking the NNP2 motif. Free 
BTFA was used for chemical shift referencing, and peaks arising from free BTFA are 
indicated by blue arrows. Spectra were acquired on a 400 MHz spectrometer at 25°C. 





Figure 4.14- 1D 19F fluorine spectra of SGTA C-terminal domain cysteine mutants 
with BTFA conjugated at positions 252 and 264 flanking the NNP3 motif. Free 
BTFA was used for chemical shift referencing, and peaks arising from free BTFA are 
indicated by blue arrows. Spectra were acquired on a 400 MHz spectrometer at 25°C. 




















































Figure 4.15- 1D 19F fluorine spectra of SGTA C-terminal domain cysteine mutants 
with BTFA conjugated at positions 272, 281, 297 and 307. Free BTFA was used for 
chemical shift referencing, and peaks arising from free BTFA are indicated by blue 
arrows. Spectra were acquired on a 400 MHz spectrometer at 25°C. The SGTA C-
terminal domain construct was present at a concentration of 250 µM. 
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4.5. 19F NMR to investigate the interaction between SGTA and Cytb5  
Hence to understand the nature and extent of the hydrophobic substrate binding C-
terminal domain of SGTA, and contributions of regions therein, aforementioned 
extrinsic 19F chemical shifts were monitored for perturbations upon substrate addition. 
The full-length tail-anchored protein cytochrome b5 (Cytb5) was used as a validated 
substrate consisting of a hydrophobic TMD helix (Fig. 4.1B). The effect of adding 
Cytb5 at molar ratios approaching 1:1 with respect to each SGTA C-terminal domain 
cysteine mutant have been shown in Figs 4.16 - 4.19. With regard to 19F NMR signals 
flanking the NNP1 motif, namely ones arising from S218C and S232C, only very subtle 
perturbations in chemical shifts can be observed, together with a decrease in the 
intensity of the signal arising from S218C upon addition of substrate (Fig. 4.16). The 
equivalent effect of substrate addition on 19F NMR signals from S235C and S248C 
positioned at either side of NNP2, appears to be different, with chemical shift 
perturbations of 0.05 ppm observed in both cases. This occurs together with a decrease 
in the intensity of both signals when Cytb5 is added (Fig. 4.17). Furthermore, the 
S252C signal flanking the NNP3 motif can be observed transitioning to a narrower 
lineshape together with a chemical shift change of 0.125 ppm upon association with 
Cytb5 (Fig. 4.18). As mentioned previously, the relatively broad 19F NMR signal 
emanating from S252C could be representative of exchange between different states. 
Therefore, addition of Cytb5 may have caused this region to select a ‘substrate-bound’ 
state, subsequently leading to the appearance of a narrower lineshape. Also, with the 
other signal flanking NNP3, namely S264C, a 0.1 ppm change in chemical shift can be 
observed upon Cytb5 addition (Fig. 4.18). Thus it appears that addition of full length 
Cytb5, incorporating its extreme C-terminal hydrophobic TMD helix, appears to induce 
changes in the local environment within the NNP region. In particular, the effect of 
substrate addition appears to be more pronounced for regions in the vicinity of the 




Figure 4.16- 1D 19F fluorine spectra of BTFA conjugated C-terminal domain 
cysteine mutants S218C and S232C, in the presence of Cytb5. Overlay of 1D 19F 
fluorine spectra in the absence of Cytb5 (in blue) and in the presence of Cytb5 at a 1:1 
molar ratio (in red). Free BTFA was used for chemical shift referencing, and peaks 
arising from free BTFA are indicated by blue arrows. Spectra were acquired on a 400 
MHz spectrometer at 25°C. The SGTA C-terminal domain construct and full-length 






Figure 4.17- 1D 19F fluorine spectra of BTFA conjugated C-terminal domain 
cysteine mutants S235C and S248C, in the presence of Cytb5. Overlay of 1D 19F 
fluorine spectra in the absence of Cytb5 (in blue) and in the presence of Cytb5 at a 1:1 
molar ratio (in red). Free BTFA was used for chemical shift referencing, and peaks 
arising from free BTFA are indicated by blue arrows. Spectra were acquired on a 400 
MHz spectrometer at 25°C. The SGTA C-terminal domain construct and full-length 





Figure 4.18- 1D 19F fluorine spectra of BTFA conjugated C-terminal domain 
cysteine mutants S252C and S264C, in the presence of Cytb5. Overlay of 1D 19F 
fluorine spectra in the absence of Cytb5 (in blue) and in the presence of Cytb5 at a 1:1 
molar ratio (in red). Free BTFA was used for chemical shift referencing, and peaks 
arising from free BTFA are indicated by blue arrows. Spectra were acquired on a 400 
MHz spectrometer at 25°C. The SGTA C-terminal domain construct and full-length 
Cytb5 were each present at a concentration of 250 µM.  
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A similar set of experiments has been carried out to understand the contribution of the 
Q-rich region to substrate binding (Fig. 4.19). These experiments show that the 19F 
NMR signal arising from S272C appears narrower upon Cytb5 binding, accompanied 
by a chemical shift change of around 0.05 ppm. Likewise, a transition to a narrow 
lineshape can be observed with the signal corresponding to the A281C. As observed in 
the NNP region, these changes could possibly be indicative of a loss of exchange 
between different states, occurring within these regions upon substrate binding. 
Furthermore, perturbations of 19F chemical shifts can also be observed with the S297C 
mutant upon Cytb5 addition, while the chemical shift of the signal arising from S307C 
mutant does not appear to be perturbed. However, an increase in peak intensity can be 
observed in the 19F NMR signals corresponding to S297C and S307C upon Cytb5 
addition.  
 
Therefore, based on the 19F NMR observations described above, it appears that the 
addition of the hydrophobic substrate Cytb5 evokes change in the non-covalent 
environment of the C-terminal domain of SGTA, to varying extents, throughout both its 
NNP and Q-rich regions.  These findings suggest that the NNP2 and NNP3 motifs are 
most affected within the NNP region (residues 213-274). In addition, the Q-rich region 
is also affected by Cytb5 upon interaction, as evident by perturbations of 19F NMR 
signals emanating from this region. Thus it appears that both regions within the C-
terminal domain (NNP and Q-rich regions) are necessary to facilitate SGTA’s 







Figure 4.19- 1D 19F fluorine spectra of BTFA conjugated C-terminal domain 
cysteine mutants S272C, A281C, S297C and S307C in the presence of Cytb5. 
Overlay of 1D 19F fluorine spectra in the absence of Cytb5 (in blue) and in the presence 
of Cytb5 at a 1:1 molar ratio (in red). Free BTFA was used for chemical shift 
referencing, and peaks arising from free BTFA are indicated by blue arrows. Spectra 
were acquired on a 400 MHz spectrometer at 25°C. The SGTA C-terminal domain 




The experiments described in this chapter demonstrate the interaction of hydrophobic 
TA substrates, namely Cytb5 and Syb2, with SGTA. The use of standard 2D NMR 
experiments (1H-15N HSQCs) has provided indications that Cyb5 and Syb2 interact with 
the distal part of the TPR capping helix and with the NNP region of the SGTA C-
terminal domain. Furthermore, the observation of extrinsic 19F NMR labels introduced 
through cysteine mutants within the C-terminal domain was, for the first time, able to 
provide observable NMR signals corresponding to regions within the C-terminal 
domain that were hitherto inaccessible due to signal absence in 1H-15N HSQC spectra, 
an absence that persisted even upon deuteration of C-terminal constructs. Subsequently, 
19F NMR findings have provided details regarding the interaction of Cytb5 with 
different regions within the C-terminal domain, namely its NNP and Q-rich regions. To 
this end, it appears that both regions within the C-terminal domain contribute to its 
interaction with Cytb5. These findings thus improve our understanding with regard to 
this crucial, yet poorly understood, substrate binding C-terminal domain of SGTA, with 
possible implications pertaining to its biological role in shielding hydrophobic 


















Biophysical characterisation of 
the interaction between SGTA 
and the intrinsic proteasomal 




Recent evidence suggests that an SGTA dependent quality control cycle involving 
hydrophobic substrates could be operating at the 19S subunit of the 26S proteasome 
(Leznicki et al., 2015). This chapter describes structural and biophysical 
characterisation of the interaction between SGTA and the proteasome, an interaction 
mediated via the intrinsic proteasomal ubiquitin receptor Rpn13 at the 19S regulatory 
subunit. Work described in this chapter has been published in Thapaliya et al. (2016).  
 
5.1 Expression and purification of Rpn13 and SGTA_TPR constructs 
In order to characterise molecular details underlying the interaction between SGTA and 
the intrinsic proteasomal ubiquitin receptor Rpn13, a C-terminal domain construct of 
Rpn13 was designed, guided by earlier mapping studies (Leznicki et al., 2015). This 
construct, encoding C-terminal residues 260-407 of human Rpn13 (hereafter referred to 
as Rpn13260-407) was successfully cloned, overexpressed in E. coli, and purified, as 
described in Chapter 2 (Materials and Methods). Rpn13260-407 was expressed in E. coli 
Rosetta cells as a fusion protein with an N-terminally placed thioredoxin A followed by 
a hexahistidine tag and a rTEV cleavage site, to improve recombinant protein 
expression and solubility. This fusion protein overexpressed in both rich and minimal 
media, both at 37°C for 4 hrs, and at 18°C overnight (Fig. 5.1). For interaction studies, 
Rpn13260-407 was overexpressed at 18ºC overnight and recovered in the soluble fraction, 
both in rich and minimal media, allowing for affinity purification, followed by size-
exclusion chromatography (SEC) to obtain pure protein samples. Recombinant 
Rpn13260-407 maintained its solubility after removal of thioredoxin A by rTEV digestion 
and could be obtained in adequate amounts to carry out binding studies using a range of 
biophysical techniques. SGTA_TPR was purified in a similar manner as described 
previously. In both cases, sample purity was assessed by SDS-PAGE, with purest 
samples used for subsequent protein-protein interaction studies (Fig. 5.2). Both 
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SGTA_TPR (residues 84-211) and Rpn13260-407 were successfully separated on a 120 
ml superdex 75 column with elution volumes of 77 ml and 69 ml, respectively (Fig. 
5.3). The Rpn13260-407 has a lower absorbance at 280 nm compared to SGTA_TPR due 




Figure 5.1- Expression of the human intrinsic proteasomal receptor Rpn13 in E. 
coli. The C-terminal domain of Rpn13 (residues 260-407) was expressed in E. coli 
Rosetta cells as a fusion protein with an N-terminally placed thioredoxin A followed by 
a hexahistidine tag (TxA_His6 + Rpn13260-407). Tests for the expression of recombinant 
Rpn13 were carried out at 18°C and 37°C, in both rich (LB) and minimal (M9) media. 
TxA_His6 + Rpn13260-407 could be successfully overexpressed in both rich and minimal 
media, as evident by the presence of bands on SDS-PAGE corresponding to the size of 
the fusion protein in both the total (T) and soluble (S) fractions of E. coli lysate. 
Overnight incubation with IPTG at 18°C was used for the subsequent production of 







Figure 5.2- Preparation of recombinant human Rpn13260-407 and SGTA_TPR. 
Rpn13260-407 was overexpressed as a fusion protein, purified by nickel affinity 
chromatography and was recovered in the eluate of the first nickel column (SDS-PAGE 
fraction: TxA_His6 + Rpn13). This was followed by affinity tag and fusion protein 
removal by treatment with rTEV (SDS-PAGE fraction: +rTEV). Pure protein was 
obtained by passing the rTEV treated fraction through a second nickel column with pure 
protein obtained in the flow-through (SDS-PAGE fraction: Rpn13260-407). Separated 
thioredoxin A and rTEV was eluted from the second nickel column (SDS-PAGE 
fraction: rTEV and TxA). SGTA_TPR was purified following a similar protocol as 
described previously. SEC was used as a final purification step for both proteins (s75 








Figure 5.3- Size exclusion chromatography of SGTA_TPR and Rpn13260-407. SEC 
was carried out on a 120 ml HiLoad 16/60 superdex 75 prep grade column at a flow rate 
of 1 ml/min. (A) SGTA_TPR has a peak elution volume of 77 ml (extinction 
coefficient: 13500 M-1cm-1). (B) Rpn13260-407 elutes at 69 ml, and has lower absorbance 
at 280 nm compared to a similar amount of SGTA_TPR due to a complete lack of 
tryptophan residues (extinction coefficient: 1490 M-1cm-1).  
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5.2 SGTA interacts with the C-terminal domain of Rpn13 
The interaction between SGTA_TPR and Rpn13260-407 was investigated by size-
exclusion chromatography (SEC) experiments. SGTA_TPR and Rpn13260-407 were 
combined in a 1:1 molar ratio and analysed by SEC on a 120 ml HiLoad 16/60 superdex 
75 column at a flow rate of 1 ml/min. The resulting elution volume (62 ml) was clearly 
indicative of the formation of a stable complex between SGTA_TPR and Rpn13260-407 
(Fig. 5.4). This was assessed based on the elution volumes of SGTA_TPR and 






Figure 5.4- Complex formation between Rpn13260-407 and SGTA_TPR as observed 
by SEC. SEC experiments carried out on a 120 ml HiLoad 16/60 superdex 75 column 
at a flow rate of 1 ml/min show the formation of a stable complex between Rpn13260-407 
and SGTA_TPR as evident by their co-elution at 62 ml when combined at a 1:1 molar 
ratio. SEC profiles of Rpn13260-407 (elution volume: 69 ml) and SGTA_TPR (elution 




Once binding had been established by SEC, isothermal titration calorimetry (ITC) was 
used to obtain binding constants (Kd) and thermodynamic parameters underlying this 
interaction. ITC experiments yield a Kd of 16.1 ± 1.4 µM  with favourable enthalpy and 
entropy values (ΔH = -3.37 ± 0.08 kcal/mol;  ΔS = 10.6 ± 0.8 cal/mol·K) (Fig. 5.5). This 
is suggestive of an interaction with SGTA_TPR driven by the formation of hydrogen 






Figure 5.5- Isothermal titration calorimetry (ITC) data showing binding of 
SGTA_TPR to Rpn13260-407. ITC experiments were carried out at 25°C, with 40 
injections of 1 µL of SGTA_TPR at a concentration of 1 mM added to a sample of 
Rpn13260-407 at a concentration of 50 µM in the reaction cell. The thermodynamic 
binding constant of this interaction as determined by ITC was Kd = 16.1 ± 1.4 µM, with 
favourable enthalpy and entropy values (ΔH = -3.37 ± 0.08 kcal/mol; ΔS = 10.6 ± 0.8 
cal/mol·K). Binding was assumed to be at one site (n = 1), to determine the binding 
affinity (Kd) and thermodynamic parameters.  
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5.3 Characterisation of the SGTA-Rpn13 interaction by solution NMR 
spectroscopy 
 
Solution NMR spectroscopy was used to characterise the interaction between 
SGTA_TPR and Rpn13260-407. Reciprocal chemical shift perturbation (CSP) 
experiments were carried out firstly by titrating unlabelled Rpn13260-407 into 15N-
labelled SGTA_TPR, and then by titrating unlabelled SGTA_TPR into 15N-labelled 
Rpn13260-407. Assignments of backbone amide resonances of SGTA_TPR and Rpn13260-
407 were obtained from the biological magnetic resonance data bank (BMRB) [BMRB 
accession numbers 5709 (SGTA_TPR) and 17286 (Rpn13260-407)].  
 
The 1H-15N HSQC spectra of SGTA_TPR displayed binding in a fast exchange regime 
upon the addition of increasing amounts of unlabelled Rpn13260-407 (Fig. 5.6). In this 
titration, widespread perturbations of backbone amide signals were observed, with 
certain amide signals not reaching saturation even in the presence of an eight-fold molar 
excess of unlabelled Rpn13260-407. However, the same titration revealed SGTA_TPR 
backbone amide signals that appear to have reached saturation at lower molar excesses 
of Rpn13260-407. As a result of these differences it was not possible to unambiguously 
disentangle signals that represented a binding equilibrium from this HSQC spectrum, 
and consequently this data could not be fit to a meaningful binding isotherm. 
Furthermore, when CSP analysis of this data (Fig. 5.7) was mapped onto the crystal 
structure of SGTA_TPR (PDB accession code 2VYI), this mapping could not provide 






















































































































































































































































































































































































































Figure 5.8- Chemical shift perturbation (CSP) analysis of the SGTA_TPR/ 
Rpn13260-407 interaction. Normalised CSP Δδav values of SGTA_TPR backbone amide 
signals upon binding to Rpn13260-407 were mapped on to the crystal structure of 
SGTA_TPR (PDB accession code 2VYI). Orthogonal cartoon views of SGTA_TPR are 
coloured according to the normalised CSP Δδav values with most perturbed residues 
shown in dark red. SGTA_TPR helices are labelled α1-α7 and the position of the central 





The 1H-15N HSQC spectra of 15N-labelled Rpn13260-407 also displayed binding in a fast 
exchange regimen upon addition of unlabelled SGTA_TPR. However, in this titration, 
backbone amide peaks corresponding to only extreme C-terminal Rpn13 residues, 
namely Met 404, Ser 405, Leu 406 and Asp 407 were perturbed upon the addition of 
increasing amounts of SGTA_TPR (Figs. 5.9 and 5.10). This titration approached 
saturation at a 1:1 molar ratio with SGTA_TPR, with the CSP data (Fig. 5.10) yielding 
a Kd of 3.27 ± 0.87  µM (Fig. 5.11). This was in agreement with the Kd value obtained 
by ITC (Fig. 5.5). 
 
In order to further understand the SGTA_TPR binding region of Rpn13, 1H- 15N 
heteronuclear NOE experiments were carried out with a four second saturation transfer 
or control period. The extreme C-terminal region of free Rpn13 (residues 403 - 407) 
was found to be highly dynamic, with negative heteronuclear NOE enhancement values 
observed in this region of the amino acid sequence (Fig. 5.12; upper panel). Upon 
addition of SGTA_TPR at a 1:1 molar ratio, these values transitioned to positive ones 
indicative of the loss of high frequency motions as a result of binding (Fig. 5.12; lower 
panel). The average heteronuclear NOE enhancement value for Rpn13 residues Asp 403 
to Asp 407 in the free and SGTA_TPR-bound state were -0.71 and 0.48, respectively, 
thus indicating the transition of the Rpn13 extreme C-terminal residues 403 - 407 to a 
more ordered state upon binding to SGTA_TPR (Fig. 5.12). Taken together with the 
CSP analysis from the Rpn13260-407 perspective, these data clearly implicate five Rpn13 
extreme C-terminal residues, namely Asp 403 to Asp 407, as the SGTA_TPR binding 












Figure 5.9- 1H-15N HSQC spectra of 15N-labelled Rpn13260-407 overlaid at different 
titration points with unlabelled SGTA_TPR. For each titration point (1:0, 1:0.2, 
1:0.5, 1:0.7, 1:1; shown in blue, light green, green, maroon, and red respectively) 1H-
15N HSQC experiments were recorded at 25°C. 15N Rpn13260-407 was present at a 












Figure 5.10- Chemical shift perturbation (CSP) values of Rpn13260-407 amide 
signals upon binding to SGTA_TPR. CSP Δδav values were calculated for C-terminal 








Figure 5.11- Normalised CSP data of the most perturbed Rpn13260-407 residues 
(405, 406, 407) upon titration with different concentrations of SGTA_TPR. NMR 
titrations were carried out at different molar ratios (1:0, 1:0.1, 1:0.2, 1:0.3, 1:0.6, 1:0.9, 
1:1.1, 1:1.9 and 1:3). Fitting was carried out using DynaFit (Kuzmic, 1996) to yield a 










































































































































































































































































5.4 The Rpn13 extreme C-terminal DMSLD pentapeptide is necessary and 
sufficient for its interaction with SGTA_TPR 
 
Informed by CSP and 1H-15N heteronuclear NOE experiments, an Rpn13 C-terminal 
domain construct devoid of its last five residues was prepared to understand the 
contribution of this region to its binding with SGTA_TPR. This construct lacking the 
Rpn13 extreme C-terminal DMSLD pentapeptide, hereafter referred to as Rpn13260-402, 
was expressed and purified (Fig. 5.13) in a manner identical to that described for 
Rpn13260-407.  
 
The Rpn13260-402 construct was first analysed by SEC to understand its association with 
SGTA_TPR. SGTA_TPR and Rpn13260-402 were mixed in a 1:1 molar ratio and 
analysed by SEC on a on a 120 ml HiLoad 16/60 superdex 75 column at a flow rate of 1 
ml/min. The resulting elution volumes (69 ml for Rpn13260-407; and 77 ml for 
SGTA_TPR) clearly demonstrated that Rpn13260-402 was not capable of interacting with 
SGTA_TPR, in particular when compared to the elution profile of the SGTA_TPR-









Figure 5.13- Preparation of recombinant human Rpn13260-402. Rpn13260-402 was 
overexpressed as a fusion protein, purified by nickel affinity chromatography and was 
recovered in the eluate of the first nickel column [SDS-PAGE fraction: TxA_His6 + 
Rpn13 (260-402)]. This was followed by affinity tag and fusion protein removal by 
treatment with rTEV (SDS-PAGE fraction: +rTEV). Pure protein was obtained by 
passing the rTEV treated fraction through a second nickel column with pure protein 
obtained in the flow-through [SDS-PAGE fraction: Rpn13 (260-402)]. Separated 
thioredoxin A and rTEV was eluted from the second nickel column (SDS-PAGE 







Figure 5.14- SEC analysis shows abrogation of the SGTA_TPR-Rpn13 interaction 
in the absence of the Rpn13 extreme C-terminal DMSLD pentapeptide. SEC 
experiments carried out on a 120 ml HiLoad 16/60 superdex 75 at a flow rate of 
1ml/min show that the disruption of the Rpn13260-407-SGTA_TPR complex occurs when 
the last five residues of Rpn13 (402-407) are absent. Rpn13260-402 combined with 
SGTA_TPR shows no indication of complex formation by SEC. The SEC profile of the 
Rpn13260-407-SGTA_TPR complex is overlaid for comparison.  
 
 
Futhermore, solution NMR CSP experiments clearly showed no changes in amide 
chemical shifts in the 1H-15N HSQC spectra of 15N-labelled SGTA_TPR even in the 
presence of a six-fold molar excess of unlabelled Rpn13260-402 (Fig. 5.15). In addition, 
ITC experiments carried out by injecting SGTA_TPR into Rpn13260-402 confirmed 









Figure 5.15- Rpn13 devoid of its extreme C-terminal residues 403-407 cannot 
interact with SGTA_TPR. 1H-15N HSQC spectra of 15N-labelled SGTA_TPR in its 
free form (in black), overlaid with the 1H-15N HSQC spectra of 15N-labelled 
SGTA_TPR with a six-fold molar excess of unlabelled Rpn13260-402 (in red). The 
absence of the C-terminal pentapeptide of Rpn13 leads to no observed perturbations of 
SGTA_TPR amide signals. 15N SGTA_TPR was present at a concentration of 200 µM. 
















Figure 5.16- Isothermal titration calorimetry (ITC) binding assay showing that 
Rpn13260-402 does not interact with SGTA_TPR. ITC experiments were carried out at 
25°C, with 20 injections of 2 µL of SGTA_TPR at a concentration of 1 mM added to a 
sample of Rpn13260-402 at a concentration of 50 µM in the calorimeter cell. 
 
Based on insight gleaned from aforementioned experiments, an Rpn13 derived extreme 
C-terminal synthetic DMSLD pentapeptide was titrated into 15N-labelled SGTA_TPR. 
This titration clearly indicated an interaction between the DMSLD pentapeptide and 
SGTA_TPR with binding in a fast exchange regimen (Fig. 5.17). Additionally, ITC 
experiments yield a dissociation constant of 71.9 ± 13.3 µM for this protein-peptide 
interaction (Fig. 5.18), with favourable enthalpy and entropy values (ΔH = -4.97 ± 0.41 





Figure 5.17- The Rpn13 extreme C-terminal DMSLD pentapeptide is necessary 
and sufficient for its interaction with SGTA_TPR. Overlaid 1H-15N HSQC spectra of 
15N-labelled SGTA_TPR at different molar ratios with the unlabelled synthetic DMSLD 
pentapeptide (1:0, 1:0.5, 1:1, 1:6, 1:8; in blue, teal, green, maroon, and red 
respectively). 15N SGTA_TPR was present at 300 µM (for titration points 1:0, 1:0.5, 
and 1:1), and at 100 µM (for titration points 1:6 and 1:8). Spectra were acquired on a 


































































Figure 5.18- ITC binding assay showing interaction of SGTA_TPR to the Rpn13 
derived DMSLD pentapeptide. The binding constant as determined by ITC for this 
interaction was, Kd = 71.9 ± 13.3 µM, with favourable enthalpy and entropy values (ΔH 
= -4.97 ± 0.41 kcal/mol; ΔS = 2.34 ± 0.04 cal/mol·K). Binding was assumed to be at one 





The DMSLD pentapeptide titrated into 15N-labelled SGTA_TPR resulted in a very 
similar pattern of CSPs of SGTA_TPR backbone amides amongst the most perturbed 
signals lining the central TPR groove when compared to 1H-15N HSQC spectra of 
SGTA_TPR upon binding to Rpn13260-407 at equivalent molar ratios (Fig. 5.19). In 
particular, SGTA_TPR residues Phe 107, Phe 128, Asn 130, Ser 159, Ala 161, and Ala 
186 show similar perturbation of amide signals upon binding to both Rpn13260-407 and to 
the DMSLD peptide, suggestive of a common binding modality. Furthermore, it was 
interesting to observe that amide signals corresponding to residues 203-209 of helix-7 
(α7) at the C-terminus of SGTA_TPR were not affected by binding to the DMSLD 
peptide. This is mainly because these amide signals are perturbed upon binding to 
Rpn13260-407 (Fig. 5.19). Therefore, it appears that C-terminal residues of SGTA_TPR 
helix-7 (α7) that do not structurally contribute to the central TPR groove, in turn do not 
form part of the peptide-binding site. This strongly points towards the central 
SGTA_TPR groove as the Rpn13 binding site, an interaction mediated by the Rpn13 
DMSLD pentapeptide. Taken together, these experiments confirm that the extreme C-
terminal DMSLD pentapeptide of Rpn13 is necessary and sufficient to facilitate its 







Figure 5.19- Comparison of Rpn13260-407 vs the DMSLD pentapeptide binding to 
SGTA_TPR. Overlay of 1H-15N HSQC spectra of 15N-labelled SGTA_TPR in its free 
state (black), bound to a 3-fold molar excess of unlabelled Rpn13260-407 (green), and 
bound to a 3-fold molar excess of the DMSLD pentapeptide (red). Backbone amide 
signals corresponding to residues with highest CSP Δδav values upon binding to either 
Rpn13260-407 or to the DMSLD pentapeptide are indicated with red arrows. Signals 
corresponding to backbone amides only affected upon binding to Rpn13260-407 but not 




5.5 The SGTA_TPR-Rpn13 interaction occurs via a two-carboxylate clamp 
mechanism 
 
TPR domains are well-established mediators of protein-protein interactions (Zhang et 
al., 2005; D’Andrea and Regan, 2003; Scheufler et al., 2000; Das et al., 1998). Their 
interaction with the C-terminal IEEVD and MEEVD motifs of Hsp70/Hsp90 
chaperones is known to occur via a ‘two-carboxylate clamp’ mode of molecular 
recognition (Dutta and Tan, 2008; Cliff et al., 2006; Zhang et al., 2005; Scheufler et al., 
2000). In this mode of binding, the main chain and side chain carboxylates present on 
the terminal aspartate of the IEEVD/MEEVD motifs are known to interact with 
conserved basic residues in the TPR groove. Given the Rpn13 sequence terminates with 
an aspartate, and the C-terminal DMSLD peptide has been found to be necessary and 
sufficient for this interaction, the possibility of a two-carboxylate clamp mechanism was 
explored by site-directed mutagenesis experiments. Structure based alignments of 
SGTA_TPR with HOP TPR domain was used to identify conserved residues within the 
TPR groove likely to participate in the formation of a two-carboxylate clamp with 
interacting peptides. Based on these alignments, residues Lys 160 and Arg 164 of 
SGTA_TPR were identified as conserved residues within the central TPR groove that 
could mediate a two-carboxylate clamp mode of binding (Fig. 5.20A). Thus, a 
K160E/R164E double mutant version of SGTA_TPR (Fig. 5.20B), was used to 
understand the effect it had on binding to Rpn13260-407 by SEC and NMR. The 
K160E/R164E double mutant SGTA_TPR was successfully expressed and purified as 
shown in Fig 5.21A. Subsequently, SEC experiments in which the K160E/R164E 
double mutant SGTA_TPR was mixed with Rpn13260-407 showed no evidence of 
complex formation even when Rpn13260-407 was present at a 3-fold molar excess over 
SGTA_TPR (Fig. 5.21B). Also, reciprocal NMR titrations adding unlabelled Rpn13260-
407 into 15N-labelled K160E/R164E double mutant SGTA_TPR with up to a 6-fold 
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molar excess of Rpn13260-407 and vice versa also showed no indication of binding (Figs. 
5.22 and 5.23). These experiments therefore confirm that the K160E/R164E double 
mutant SGTA_TPR is sufficient to disrupt complex formation between SGTA_TPR and 
Rpn13260-407. Consequently, this establishes a two-carboxylate clamp mechanism of 
binding between the terminal aspartate of Rpn13 and the conserved Lys 160 and Arg 




Figure 5.20- The conserved two-carboxlate clamp mode of molecular recognition 
by TPR domains. (A) Sequence alignment comparing helix-5 (α5) of SGTA_TPR to 
equivalent helices of HOP TPR domains, highlighted with conserved lysine and 
arginine residues that clamp terminal carboxylates present on binding partners. (B) 
Conserved residues present in the central groove of SGTA_TPR most likely to facilitate 
the two-carboxylate clamp mediated recognition of peptides are highlighted in ball and 
stick representation based on the sequence alignment. Based on crystal structure of 





Figure 5.21- Preparation of the K160E/R164E double mutant SGTA_TPR and 
Rpn13260-407 to probe the two-carboxylate clamp mechanism of binding. (A) SDS-
PAGE showing purification results of Rpn13260-407 (lanes: TxA_His6 + Rpn13260-407 and 
Rpn13260-407) and of K160E/R164E double mutant SGTA_TPR (lanes: TxA_His6 + 
K160E/R164E TPR and K160E/R164E TPR). (B) SEC experiments carried out on a 
120 ml HiLoad 16/60 superdex 75 at a flow rate of 1ml/min demonstrate that the 
K160E/R164E double mutant SGTA_TPR does not co-elute with Rpn13260-407 when 







Figure 5.22- The K160E/R164E double mutant SGTA_TPR disrupts its interaction 
with Rpn13260-407. Overlay of 1H-15N HSQC spectra of 15N-labelled K160E/R164E 
SGTA_TPR in its free form (black), and in the presence of a six-fold molar excess of 
unlabelled Rpn13260-407 (red). Spectra were acquired on a 500 MHz spectrometer at 




















Figure 5.23- Rpn13260-407 and K160E/R164E double mutant SGTA_TPR do not 
interact. Overlay of 1H-15N HSQC spectra of 15N-labelled Rpn13260-407 in its free form 
(black), and with a six-fold molar excess of unlabelled K160E/R164E SGTA_TPR 
(red). Spectra were acquired on a 500 MHz spectrometer at 25°C. 15N Rpn13260-407 was 












Rpn13 260-407 + K160E/R164E TPR (1:6) 
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5.6 Intermolecular PRE experiments to delineate the SGTA-Rpn13 binding 
interface 
 
Once the two-carboxylate clamp mechanism of binding had been established as 
described above, intermolecular paramagnetic relaxation enhancement (PRE) 
experiments were carried out to further understand details pertaining to the 
SGTA_TPR/Rpn13 binding interface. These were to include details concerning the 
region of entry of the Rpn13′s C-terminal extension into the central groove of 
SGTA_TPR, the orientation of the DMSLD pentapeptide within the SGTA_TPR 
groove, and possible conformations of the pentapeptide within the groove. For these 
investigations, a site-directed paramagnetic spin-label (MTSL) was introduced via a 
K398C mutant of Rpn13260-407. The position of the K398C mutant of Rpn13260-407 is 
shown in Fig. 5.24A. 15N-labelled SGTA_TPR and K398C Rpn13260-407 were purified in 
a similar manner as described previously (Fig. 5.24B). Proximity dependent line 
broadening of 15N-labelled SGTA_TPR backbone amide signals was monitored for 
intermolecular PRE effects upon addition of MTSL labelled K398C Rpn13260-407 (Fig. 
5.25A). Significant line broadening effects on SGTA_TPR backbone amides were 
observed upon binding to MTSL labelled K398C Rpn13260-407 (Fig. 5.25). These effects 
could be clearly observed in SGTA_TPR backbone amide peaks corresponding to 
residues Met-102, Lys-103, Glu-105, Lys-137, Ser-170, Asn-173, Ser-197, Lys-200, 
Ile-201, Glu-203, Ser-211. When PRE intensity ratios (Fig. 5.25B) were mapped onto 
the crystal structure of SGTA_TPR (PDB code: 2VYI) these residues were all found to 
be present on the lower edge of its concave surface (Fig. 5.26), lining the entry to the 
central groove. This finding revealed that the paramagnetic probe on K398C Rpn13260-
407 was present within a 25 Å distance of these residues. Taken together with CSP data 
(Fig. 5.19), this confirms that the Rpn13260-407 C-terminal extension enters the 
SGTA_TPR groove via this lower edge of its concave surface. Furthermore, the 
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position of the paramagnetic spin label confirms the orientation of the DMSLD peptide 
within the SGTA_TPR groove. In addition, mapping of SGTA_TPR residues affected 
by intermolecular PRE dependent line broadening onto the crystal structure of 
SGTA_TPR (Fig. 5.26) reveals that the Rpn13 C-terminal DMSLD pentapeptide could 
be sampling a lot of conformational space within the SGTA_TPR groove. This has lead 
to the speculation that the DMSLD peptide may be present in more than one 




Figure 5.24- Preparation of an Rpn13 C-terminal cysteine mutant for site-directed 
spin labelling studies. (A) Schematic of the Rpn13 C-terminal domain with the 
position of the K398C used for site-directed paramagnetic spin labelling studies. (B) 
SDS-PAGE results showing preparation of 15N SGTA_TPR and unlabelled K398C 





Figure 5.25- Intermolecular paramagnetic relaxation enhancement (PRE) 
experiments. (A) Regions of the 1H-15N HSQC spectra of 15N-labelled SGTA_TPR 
upon binding to either the diamagnetic (dMTSL) probe labelled K398C Rpn13260-407 
(blue), or in the presence of the paramagnetic (MTSL) probe labelled K398C Rpn13260-
407 (red) showing distance dependent line broadening. (B) Paramagnetic relaxation 
enhancement (PRE) intensity ratios of SGTA_TPR residues upon binding to the spin 








Figure 5.26- PRE induced line-broadening mapped onto crystal structure of 
SGTA_TPR. Orthogonal cartoon views of SGTA_TPR (PDB accession code 2VYI), 
showing SGTA_TPR residues affected by intermolecular PRE induced line broadening 
upon binding to MTSL labelled K398C Rpn13260-407. Backbone amides within 




5.7 SGTA_TPR/Rpn13 C-terminal DMSLD pentapeptide complex 
CSP experiments, mutagenesis data, together with insights gleaned from paramagnetic 
spin labelling studies, were used to generate a model of a 1:1 complex using the 
HADDOCK based semi-rigid, data-driven approach. The coordinates of the DMSLD 
peptide were obtained from the solution NMR structure of Rpn13 (PDB accession code: 
2KR0). On the other hand, the coordinates of SGTA_TPR were obtained from its 
crystal structure (PDB accession code: 2VYI). The three lowest energy HADDOCK 
clusters of the SGTA_TPR/DMSLD complex were analysed (Table 5.1; Fig. 5.27). 
 
 
 Table 5.1- Energetic parameters obtained for the three best clusters of 
SGTA_TPR/DMSLD peptide complex calculated using HADDOCK. 
 
























Cluster1	   -­‐107.6	  +/-­‐2.1	   40	   3.6	  +/-­‐	  0.1	   -­‐21.1	  +/-­‐	  4.8	   33.4	  +/-­‐	  17.89	   1119.1	  +/-­‐	  63.2	   -­‐545.0	  +/-­‐	  24.0	   19.2	  +/-­‐	  4.9	   -­‐1.8	  Cluster2	   	  -­‐98.8	  +/-­‐	  6.5	   5	   1.0	  +/-­‐	  0.1	   -­‐17.8	  +/-­‐	  5.8	   97.8	  +/-­‐	  19.63	   1234.2	  +/-­‐	  12.8	   -­‐533.0	  +/-­‐	  37.4	   15.7	  +/-­‐	  1.5	   -­‐1.4	  Cluster3	   -­‐92.2	  +/-­‐	  18.5	   4	   3.9	  +/-­‐	  0.1	   -­‐22.7	  +/-­‐	  2.8	   38.9	  +/-­‐	  20.28	   1009.9	  +/-­‐	  73.8	   -­‐455.2	  +/-­‐	  93.0	   17.7	  +/-­‐	  2.7	   -­‐1.1	  	  
 
Based on this model, the SGTA_TPR residues present at the binding interface with the 
DMSLD peptide are Asn-99, Asn-130, Lys- 160 and Arg-164, with Lys-160 and Arg-
164 clamping the two carboxylates present on the terminal aspartate of the DMSLD 
peptide (Fig. 5.28). Although this structure represents the two-carboxylate clamp 
mechanism, it must be noted that the peptide is likely to be present in multiple 









Figure 5.27- SGTA_TPR/DMSLD peptide complex HADDOCK results. A) The 
three top scoring clusters of the SGTA_TPR/DMSLD complex generated by 
HADDOCK. B) Overlay of HADDOCK-generated top scoring clusters of the 







Figure 5.28- SGTA_TPR/ DMSLD peptide complex generated using the 
HADDOCK approach. The SGTA_TPR crystal structure is shown in cartoon 
representation labelled with TPR helices α1-α7. The Rpn13 derived DMSLD peptide is 
shown as sticks. The inset highlights SGTA_TPR residues Asn-99, Asn-130, Lys-160 
and Arg-164 that form a network of electrostatic interactions with the terminal aspartate 
on the DMSLD peptide.  
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5.8 Summary 
It is clear based on abovementioned experiments that SGTA interacts with the 
proteasome at its 19S regulatory particle via a two-carboxylate clamp mediated 
molecular recognition event, involving the extreme C-terminal residues of the intrinsic 
proteasomal ubiquitin receptor Rpn13 binding to conserved basic residues present in the 
SGTA_TPR groove. Furthermore, the extreme C-terminal DMSLD pentapeptide of 
Rpn13 is necessary and sufficient to facilitate this interaction. It also appears that this 
interaction is dynamic with the DMSLD pentapeptide sampling conformational space 
within the SGTA_TPR groove. These findings provide molecular details underlying a 
potential SGTA dependent quality control cycle operating at the 19S regulatory particle 
of the 26S proteasome, and could have implications in determining the fate of MLPs 





















The aim of this thesis is to extend our knowledge of the SGTA protein’s structure and 
its role in proteostasis, with a key focus on elucidating molecular details underlying its 
function to triage hydrophobic substrates in the cytosol. The results presented in this 
work describe the modular assembly of full-length SGTA in vitro (Chapter 3), its 
interaction with hydrophobic substrates (Chapter 4), and details of SGTA’s association 
with the intrinsic proteasomal ubiquitin receptor Rpn13 at the 19S regulatory particle of 
the 26S proteasome (Chapter 5). In this chapter I critically evaluate aforementioned 
results and elaborate on their relevance in light of SGTA’s biological role in 
maintaining cytosolic protein homeostasis.  
 
6.1. Structure and dynamics of full-length SGTA in vitro 
Our understanding of the assembly of full-length SGTA in vitro has been extended by 
work presented in Chapter 3. Thus far, biophysical characterization of SGTA was 
limited to isolated domains, with high-resolution structures of its N-terminal domain 
determined by solution NMR spectroscopy, and of its central TPR domain by X-ray 
crystallography (Darby et al., 2014; Dutta and Tan, 2008). The reason as to why 
characterisation of full-length SGTA has not been possible by conventional structural 
biology methods alone (such as X-ray crystallography, NMR and cryo-EM) could be 
due to the intrinsic flexiblilty of linker regions between domains and a particularly 
challenging C-terminal region that has defied these methods to understand its structure. 
This study presents a hybrid approach, one that combines a range of biophysical 
techniques to include solution NMR spectroscopy, CD spectroscopy, and non 
dissociative nano-electrospray ionization mass spectrometry (Native MS) to reveal 
significant insights into the domain organization and conformation of SGTA in the 
context of the full-length protein.  
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One of the findings of this study is that in full-length SGTA each of its domains are 
independent of one another. This is likely due to the presence of flexible linkers 
between folded domains. In addition, CD spectroscopy has identified the presence of 
alpha-helical regions within the C-terminal domain. Whereas solution NMR studies 
indicate the presence of unstructured regions within the C-terminal domain, it is likely 
that these alpha-helical elements lie in regions for which signals have not been visible 
by standard solution NMR methods (Fig. 3.13). However it has not been possible to 
pinpoint the exact location of these alpha-helical regions within the C-terminal domain, 
largely due to the fact that intrinsic aggregation of this domain, together with its 
tendency to form hydrogels at higher concentrations, has hindered typical high-
resolution structural analyses by standard methods.  
 
Also, in this study, native MS experiments have revealed, for the first time, that the 
excised C-terminal region of SGTA exists as a dimer in solution. Furthermore, these 
experiments have also confirmed that full-length SGTA exists as a dimer in vitro. 
However, with respect to C-terminal dimerisation, the exact nature of this interaction is 
yet to be understood. This is mainly due to the lack of NMR signals corresponding to 
regions within the C-terminal domain, which is suggestive of interaction on an 
undetectable timescale, and therefore it has not been possible to obtain the precise 
location of motifs that could be driving this process of dimerisation. Together with 
information obtained from NMR relaxation experiments, it is evident that full-length 
SGTA can adopt a ‘closed’ conformation in solution, driven by C-terminal dimerisation 
which thereby constrains the mobility of the central TPR domains.  
 
The presence of this closed conformation of full-length SGTA is likely to have 
implications regarding its recognition of hydrophobic substrates. However it is yet to be 
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fully understood as to whether this ‘closed’ state of SGTA is representative of a 
substrate bound conformation, or if this on the other hand, represents an apo 
conformation of SGTA. Nonetheless, it is interesting to speculate whether substrate 
binding and release could result from an interplay between ‘closed’ and ‘open’ 
conformations. One possibility is that the SGTA C-terminal closing action 
accommodates the substrate, thereby masking it from the surrounding aqueous cytosol, 
in a manner that has recently been described with regard to the downstream TA 
targeting factor Get3’s ability to bind hydrophobic TMD helices (Mateja et al., 2015). 
In the crystal structure of the Get3-TA complex, a single TMD helix is shielded by a 
large hydrophobic groove formed at the Get3 dimer interface (Mateja et al., 2015). 
However, in the case of Get3, this substrate bound ‘closed’ conformation is stabilized 
by ATP binding, whereas SGTA is devoid of such nucleotide binding or hydrolysis 
capability. In any case, a tweezer-like opening and closing model of substrate binding 
remains a possibility and should be pursued further in order to understand the 
mechanism of substrate binding by SGTA. 
 
6.2. SGTA interacts with hydrophobic substrates via its C-terminal domain 
A key function of SGTA is to shield hydrophobic substrates from exposure to the 
aqueous cytosol. The C-terminal domain of SGTA is functionally important for binding 
MLPs and related hydrophobic substrates, and is responsible for the inhibitory effect of 
SGTA overexpression on MLP degradation (Leznicki and High, 2012; Liou and Wang, 
2005). Work presented in Chapter 4 of this thesis provides further insights with respect 
to the nature and extent of this substrate-binding region of SGTA.  
 
First of all, 2D NMR titrations of the 15N labeled TPR_NNP construct with unlabeled 
TA proteins showed that both substrates associated to a certain extent with the capping 
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helix of SGTA_TPR. This identifies a potential substrate-binding role of the TPR 
capping helix that is located adjacent to the C-terminal domain. These experiments have 
also demonstrated that TA substrates interact with the NNP region of the SGTA C-
terminal domain. However, due to a considerable absence of intrinsic NMR signals 
corresponding to this region, this observation could not be unambiguously verified. 
Nonetheless, the observation of extrinsic 19F NMR labels introduced through cysteine 
mutants within the C-terminal domain was, for the first time, able to provide observable 
NMR signals corresponding to both NNP and Q-rich regions within the C-terminal 
domain. Using Cytb5 as a TA substrate, perturbations of 19F NMR signals could be 
observed within the NNP region, and were particularly evident in signals arising from 
cysteine mutants flanking the NNP2 and NNP3 motifs within the SGTA C-terminal 
domain. Similarly, perturbations of 19F NMR signals could be observed in the SGTA Q-
rich region upon interaction with Cytb5. Thus it appears that in the case of the TA 
protein Cytb5, consisting of a TMD helix of moderate hydrophobicity, both NNP 
(motifs 2 and 3) and Q-rich regions are required for its association with SGTA. It could 
be the case that substrates with differing extents of hydrophobicity require a greater, or 
lesser, degree of shielding by the C-terminal domain. For instance, MLPs presenting a 
greater extent of surface exposed hydrophobicity may utilise the entirety of the C-
terminal domain to avoid exposure of vulnerable regions. It could also be the case that 
for such MLPs more than one SGTA dimer may be required to confer sufficient 
protection.  
 
Previous studies have shown that the C-terminal Q-rich region alone is unable to bind 
larger hydrophobic substrates such as the GLUT1 membrane transporter, however the 
same region was shown to be sufficient for associating with smaller hydrophobic 
peptides (Liou and Wang, 2005). Therefore, it appears that the Q-rich region may act as 
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an accessory when dealing with larger substrates whereas the NNP region provides the 
first line of protection for MLP and TA proteins in the cytosol. This could explain the 
requirement for an expansion of NNP motifs within the C-terminal domain of human 
SGTA, which may stem from an evolutionary need to triage an increasingly diverse 
repertoire of hydrophobic substrates, in comparison to substrates presented to its yeast 
counterpart Sgt2. Unlike the metazoan homologues, Sgt2 only has one NNP motif 
within its C-terminal domain. Similarly, there appears to have been an evolutionary 
rearrangement in the Q-rich region of SGTA, as can be gleaned from sequence 
comparison with Sgt2. Glutamine residues in Sgt2 are more scattered throughout its C-
terminal region, rather than being present as stretches consisting of up to three 
glutamines at a time, as can be observed in SGTA’s Q-rich region. This could also 
increase mammalian SGTA’s effectiveness in masking regions of hydrophobicity. Thus, 
in order to gain a better understanding of SGTA’s hydrophobic substrate binding region 
it would be particularly useful to characterise its binding with different MLP and TA 
proteins, with varying extents of surface exposed hydrophobicity.  
 
6.3 SGTA associates with the intrinsic proteasomal ubiquitin receptor 
Rpn13 via a carboxylate clamp mechanism 
Work presented in Chapter 5 of this thesis was able to conclusively demonstrate that 
SGTA is recruited to the 19S regulatory particle of the 26S proteasome via the intrinsic 
proteasomal ubiquitin receptor Rpn13. In particular, this study has determined that the 
extreme C-terminal pentapeptide of Rpn13 is necessary and sufficient to facilitate this 
interaction, which occurs through a two-carboxylate clamp mediated molecular 
recognition event of said pentapeptide by the central TPR domain of SGTA. 
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The binding affinity between SGTA_TPR and Rpn13, in the context of both the isolated 
pentapeptide and the Rpn13260-407 C-terminal construct, as measured by ITC yields Kd 
values on the tens of micromolar scale. These Kd values match well with the Kd 
obtained from our NMR titration of unlabelled SGTA_TPR into 15N- labelled Rpn13260-
407 (Fig. 5.9). However, from the perspective of the reciprocal titration (Figs. 5.6 and 
5.17), it was not possible to fit the data to a meaningful isotherm, as saturation could not 
be achieved even after titrating to a 1:8 molar ratio (SGTA_TPR: Rpn13260-407 or 
DMSLD pentapeptide). This suggests weaker binding than that implied by the values 
obtained using ITC which is intriguing given the results from the reverse experiment. 
Moreover Kd values obtained by ITC are consistent with reported values of other TPR 
domains interacting with MEEVD/IEEVD peptides of Hsp70 and Hsp90 molecular 
chaperones, respectively, via a similar two-carboxylate clamp mechanism (Scheufler et 
al., 2000). More pertinently, similar Kd values have been reported by ITC with the TPR 
domain of SGTA’s C. elegans homolog upon interaction with MEEVD/IEEVD 
peptides of Hsp70/90 chaperones (Worrall et al., 2008). Therefore, based on the 
literature around TPR-carboxylate clamps, many low micromolar range Kd values have 
been reported as measured by ITC (Scheufler et al., 2000; Worrall et al., 2008) and 
sometimes by CD spectroscopy (Cliff et al., 2005). An explanation for the widespread 
perturbations of amide signals of 15N-labelled SGTA_TPR (Figs. 5.6 and 5.17), 
observed upon binding to unlabeled Rpn13, could be that the titration from the 15N-
labelled SGTA_TPR perspective is not purely representative of a binding equilibrium. 
There may well be peaks that approach saturation, while ones that defy saturation could 
represent some other underlying process. However, from the perspective of 15N- 
labelled Rpn13260-407 (Fig. 5.9), upon titration with unlabelled SGTA_TPR, it is clear 
that this is representative of a binding equilibrium thus is in agreement with Kd values 
obtained by ITC.  
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The significance of the carboxylate clamp dependent binding of SGTA to the C-
terminal DEUBAD domain of Rpn13 can be understood from recent work carried out in 
cultured mammalian cells (Thapaliya et al., 2016; Leznicki et al., 2015). These studies 
suggest that recruitment of exogenous SGTA to the proteasome can subsequently 
reduce the degradation of MLPs. It is known that overexpression of exogenous SGTA 
in mammalian cells results in an increase in the steady state level of model MLPs, an 
effect that could be attributed to a delay in MLP degradation at the proteasome 
(Wunderley et al., 2014). Also, it has been shown that the overexpression of an SGTA 
double mutant with a defective carboxylate clamp does not have the aforementioned 
stabilization effect on MLPs (Leznicki et al., 2015). In addition, it has been shown that 
co-expression of SGTA with Rpn13 variants with defective SGTA binding regions 
leads to a stabilization of MLPs (Thapaliya et al., 2016). Taken together, these findings 
favour the idea that exogenous SGTA can enhance model MLP levels, an effect that 
relies on its binding to the extreme C-terminal pentapeptide of Rpn13. As far as 
endogenous SGTA is concerned, the importance of its interaction with Rpn13 is yet to 
be fully understood. Nonetheless, is has been suggested that binding of endogenous 
SGTA to Rpn13 can influence MLP degradation (Leznicki et al., 2015). 
 
6.4 SGTA’s role in the quality control of hydrophobic substrates 
There is a growing body of evidence to illuminate SGTA’s role in enforcing quality 
control of mislocalized hydrophobic substrates, thereby contributing to cytosolic 
proteostasis. The contribution of SGTA to cytosolic quality control of MLPs was first 
investigated in a study by Leznicki and High (2012), in which it was shown that SGTA 
is capable of reversing ubiquitination of MLPs instigated by BAG6. This led to the 
proposal of a SGTA/BAG6 quality control cycle that decided the fate of MLPs in the 
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cytosol, leading to either BAG6 dependent ubiquitination and proteasomal degradation, 
or SGTA dependent deubiquitination. In agreement with this proposed SGTA/BAG6 
cycle, the High group have also shown that SGTA overexpression selectively delays the 
proteasomal degradation of a model mislocalized protein (MLP) but not a related 
control protein with a disrupted hydrophobic region (Wunderley et al., 2014). In 
addition, it has also been demonstrated that the overexpression of exogenous SGTA 
increases steady state MLP levels whilst a knockdown of endogenous SGTA reduces 
steady state MLP levels (Wunderley et al., 2014). It is also worth noting that a 
completely independent study by Waheed et al. (2016) found that SGTA 
overexpression in the presence of the HIV Vpu protein leads to the stabilization of a 
non- glycosylated form of the endogenous type II membrane protein tetherin, which 
accumulates in the cytosol. For all these reasons, it is becoming increasingly apparent 
that SGTA is a key effector in deciding the fate of aberrant and mislocalised membrane 
proteins. 
 
The results presented in this thesis provide insights into the possibility of a SGTA 
dependent quality control cycle operating at the 19S regulatory particle of the 
proteasome (Fig. 6.1). As full-length SGTA is present as a homodimer, it is possible for 
its individual TPR domains to associate with different quality control factors, whilst its 
C-terminal domain is bound to hydrophobic substrates. It is known that SGTA can form 
complexes with both Hsp90 and Hsp70 molecular chaperones (Liou and Wang, 2005; 
Liu et al., 1999), and with the intrinsic proteasomal ubiquitin receptor Rpn13 
(Thapaliya et al., 2016; Leznicki et al., 2015) via its central TPR domain. Thus it is 
plausible to envision a scenario in which SGTA-bound substrates find themselves in 
close proximity to these ATP-dependent molecular chaperones, whilst at the same time 
being associated with the 19S regulatory particle of the proteasome. This could provide 
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substrates that arrive at the proteasome with access to the ATP-dependent (Hsp70/90) 
chaperone networks.  
 
Furthermore, it is known that BAG6 interacts with the intrinsic proteasomal receptor 
Rpn10, also present at the 19S regulatory particle, located in close proximity to Rpn13 
(Kikukawa et al., 2005; Minami et al., 2010). Thus on one hand it is possible for MLPs 
at the proteasome to be ubiquitinated by the actions of the E3 ligase RNF126 via BAG6 
(Hessa et al., 2011; Rodrigo Brenni et al., 2014). On the other hand, it is also possible 
for SGTA bound substrates to be subjected to deubiquitination (Leznicki and High, 
2012; Wunderley et al., 2014). At the 19S regulatory particle, the mechanism whereby 
SGTA promotes substrate deubiquitination could be explained by the proximity that 
SGTA-bound substrates gain to the UCH37 deubiquitinase, which is in turn achieved 
through SGTA’s carboxylate clamp dependent association with Rpn13. As Rpn13 
activates UCH37 via an interaction with its C-terminal DEUBAD domain (Sahtoe et al., 
2015; VanderLinden et al., 2015), this provides SGTA bound MLP substrates with an 
opportunity for selective deubiquitination. Taken together, it appears extremely likely 
that SGTA/BAG6 dependent cycles of MLP substrate ubiquitination and 
deubiquitination could take place at the 19S regulatory particle of the proteasome, in 
addition to such cycles occuring in the cytosol (Leznicki and High 2012; Wunderley et 
al., 2014). The outcome of such a cycle could be either ubiquitination and proteasomal 
degradation, or deubiquitination and stabilisation (Fig. 6.1). 






Figure 6.1.- A putative SGTA/BAG6 quality control cycle of MLPs operating at 
the proteasome. MLPs could arrive at the 19S regulatory particle of the proteasome via 
either BAG6 or SGTA, mediated by intrinsic proteasomal receptors Rpn10 and Rpn13, 
respectively (Thapaliya et al., 2016; Leznicki et al., 2015; Kikukawa et al., 2005; 
Minami et al., 2010). MLPs bound to BAG6 are selectively ubiquitinated by the actions 
of the E3 ligase, RNF126 (Krysztofinska et al., 2016; Rodrigo Brenni et al., 2014). 
Whereas MLPs bound to SGTA could be subjected to deubiquitination at the 
proteasome through the actions of UCH37. This could occur due to activation of the 
UCH37 deubiquitinase upon binding to Rpn13 (Sahtoe et al., 2015; VanderLinden et 
al., 2015). These concerted actions could lead to cycles of ubiquitination and 
deubiquitination of MLPs at the proteasome. In addition, the Hsp70/90 molecular 
chaperones could have a role to play in this process due to their carboxylate clamp 
dependent binding to the TPR domain of SGTA (Liou and Wang, 2005; Liu et al., 
1999).  
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However, the physiological role of a SGTA/BAG6 cycle operating at the proteasome 
remains to be understood. It appears unlikely that the physiological role of SGTA’s 
recruitment to the proteasome would be to rescue terminally misfolded MLPs from 
degradation. This is due to the fact that, undegraded MLPs are known to have an 
increased propensity to aggregate (Wunderley et al., 2014). For transiently unfolded 
MLPs and precursors this SGTA/BAG6 cycle at the proteasome could provide a final 
opportunity at productive folding or membrane targeting before being subjected to 
proteasomal recycling. Also, it is tempting to speculate that stabilisation of hydrophobic 
substrates resulting from the SGTA-Rpn13 interaction may constitute a pathway that 
rescues prematurely ubiquitinated tail-anchored membrane proteins, thereby extending 
their window of opportunity for productive membrane insertion. 
 
6.5 Concluding remarks 
Recent years have seen a growing interest to understand molecular mechanisms 
underlying intracellular protein aggregation, unsurprisingly due to its relevance to the 
pathogenesis of numerous human diseases. In this regard, SGTA has emerged as a 
central regulator for the quality control of membrane proteins that mislocalise to the 
cytosol (Leznicki et al., 2015; Wunderley et al., 2014; Xu et al., 2012; Leznicki and 
High, 2012). Therefore, this thesis aims to further our knowledge of SGTA by 
providing a comprehensive biophysical study focusing on quality control pathways 
within which it operates.  
 
Biophysical characterization of full-length SGTA (Chapter 3) has for the first time 
provided evidence of a ‘closed’ conformation of SGTA in solution, mediated by the 
dimerisation of its C-terminal domain. However, it has not been possible to discern the 
precise region within the C-terminal domain that facilitates dimerisation. Further work 
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will be required to identify such regions within the C-terminal domain. One approach 
would be to generate a number of C-terminal truncated variants of SGTA, followed by 
native MS analysis to identify the minimal region required for C-terminal dimerisation. 
Also the existence of ‘open’ vs ‘closed’ conformations of full-length SGTA remains a 
possibility, and should be investigated further in relation to its association with 
hydrophobic substrates. 
 
Work presented in Chapter 4 investigates the interaction of SGTA with hydrophobic 
substrates, using tail-anchored membrane proteins as examples. This work has 
identified regions of the TPR capping helix, together with regions within the C-terminal 
domain of SGTA, namely the NNP motifs and the Q-rich region, to be necessary for 
substrate binding. An extension of work presented in this thesis would be to use this 
information to design mutants targeting regions in the TPR capping helix and in the C-
terminal domain of SGTA for overexpression studies in cultured mammalian cells to 
gain functional insights as to how these regions contribute to the stabilization of model 
MLPs. Together with further work in vitro to understand SGTA’s interaction with 
substrates that present varying degrees of hydrophobicity, functional studies in 
mammalian cells would be particularly useful in understanding the process of 
hydrophobic substrate recognition, binding and release by SGTA. 
 
The recruitment of SGTA to the proteasome via a carboxylate clamp dependent binding 
to the intrinsic proteasomal receptor Rpn13 provides the molecular basis for a putative 
MLP quality control cycle at the proteasome (Chapter 5). Such a cycle would constitute 
a process whereby successive cycles of substrate ubiquitination and deubiquitination 
occurring at the 19S regulatory particle of the proteasome, as a result of the concerted 
actions of associated BAG6 and SGTA, would eventually determine the fate of MLPs 
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that arrive at the proteasome. However, further work to reconstitute such a 
SGTA/BAG6 cycle at the proteasome with purified components, together with assays in 
cultured mammalian cells, would be necessary to conclusively demonstrate mechanisms 
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Synthetic gene sequences (with translated sequence) used for plasmid cloning 
 
A1. Codon optimised sequence encoding full-length human SGTA 
atggacaacaagaagcgcctggcctacgccatcatccagttcctgcatgaccagctccgg   
 M  D  N  K  K  R  L  A  Y  A  I  I  Q  F  L  H  D  Q  L  R  
cacgggggcctctcgtccgatgctcaggagagcttggaagtcgccatccagtgcctggag   
 H  G  G  L  S  S  D  A  Q  E  S  L  E  V  A  I  Q  C  L  E  
actgcgtttggggtgacggtagaagacagtgaccttgcgctcccccagactctgccggag   
 T  A  F  G  V  T  V  E  D  S  D  L  A  L  P  Q  T  L  P  E  
atatttgaagcggctgccacgggcaaggagatgccgcaggacctgaggagccccgcgcga   
 I  F  E  A  A  A  T  G  K  E  M  P  Q  D  L  R  S  P  A  R  
accccgccttccgaggaggactcagcagaggcagagcgcctcaaaaccgaaggaaacgag   
 T  P  P  S  E  E  D  S  A  E  A  E  R  L  K  T  E  G  N  E  
cagatgaaagtggaaaactttgaagctgccgtgcatttctacggaaaagccatcgagctc   
 Q  M  K  V  E  N  F  E  A  A  V  H  F  Y  G  K  A  I  E  L  
aacccagccaacgccgtctatttctgcaacagagccgcagcctacagcaaactcggcaac   
 N  P  A  N  A  V  Y  F  C  N  R  A  A  A  Y  S  K  L  G  N  
tacgcaggcgcggtgcaggactgtgagcgggccatctgcattgacccggcctacagcaaa   
 Y  A  G  A  V  Q  D  C  E  R  A  I  C  I  D  P  A  Y  S  K  
gcctacggcaggatgggcctggcgctctccagcctcaacaagcacgtggaggccgtggct   
 A  Y  G  R  M  G  L  A  L  S  S  L  N  K  H  V  E  A  V  A  
tactacaagaaggctctggagctggaccccgacaacgagacatacaagtccaacctcaag   
 Y  Y  K  K  A  L  E  L  D  P  D  N  E  T  Y  K  S  N  L  K  
atagcggagctgaagctgcgggaggcccccagccccacgggaggcgtgggcagcttcgac   
 I  A  E  L  K  L  R  E  A  P  S  P  T  G  G  V  G  S  F  D  
atcgccggcctgctgaacaaccctggcttcatgagcatggcttcgaacctaatgaacaat   
 I  A  G  L  L  N  N  P  G  F  M  S  M  A  S  N  L  M  N  N  
ccccagattcagcagctcatgtccggcatgatttcgggtggcaacaaccccttgggaact   
 P  Q  I  Q  Q  L  M  S  G  M  I  S  G  G  N  N  P  L  G  T  
cccggcaccagcccctcgcagaacgacctggccagcctcatccaggcgggccagcagttt   
 P  G  T  S  P  S  Q  N  D  L  A  S  L  I  Q  A  G  Q  Q  F  
gcccagcagatgcagcagcagaacccagagttgatagagcagctcaggagccagatccgg   
 A  Q  Q  M  Q  Q  Q  N  P  E  L  I  E  Q  L  R  S  Q  I  R  
agtcggacgcccagcgccagcaacgacgaccagcaggagtga   
 S  R  T  P  S  A  S  N  D  D  Q  Q  E  -   
 
 
A2. Codon optimised sequence encoding full-length human cytochrome b5 
atggcagaacagagtgatgaagccgttaaatactataccctggaagaaatccagaaacac   
 M  A  E  Q  S  D  E  A  V  K  Y  Y  T  L  E  E  I  Q  K  H  
aaccatagcaaaagcacctggctgattctgcatcataaagtgtatgatctgaccaaattt   
 N  H  S  K  S  T  W  L  I  L  H  H  K  V  Y  D  L  T  K  F  
ctggaagaacaccctggtggtgaagaagttctgcgcgaacaggcaggcggtgatgcaacc   
 L  E  E  H  P  G  G  E  E  V  L  R  E  Q  A  G  G  D  A  T  
gaaaattttgaagatgttggtcatagcaccgatgcacgtgaaatgagcaaaacctttatt   
 E  N  F  E  D  V  G  H  S  T  D  A  R  E  M  S  K  T  F  I  
atcggtgaactgcatcctgatgatcgtccgaaactgaataaaccgcctgaaaccctgatt   
 I  G  E  L  H  P  D  D  R  P  K  L  N  K  P  P  E  T  L  I  
accaccattgatagcagcagcagttggtggaccaattgggttattccggcaattagcgca   
 T  T  I  D  S  S  S  S  W  W  T  N  W  V  I  P  A  I  S  A  
gttgcagttgcactgatgtatcgtctgtatatggcagaagattaa   




A3. Codon optimised sequence encoding full length human Syb2 
atgagcgcaaccgcagccaccgcaccgcctgcagcaccagccggtgaaggtggtcctccg   
 M  S  A  T  A  A  T  A  P  P  A  A  P  A  G  E  G  G  P  P  
gcaccgcctccgaatctgaccagcaatcgtcgtctgcagcagacccaggcacaggttgat   
 A  P  P  P  N  L  T  S  N  R  R  L  Q  Q  T  Q  A  Q  V  D  
gaagttgttgatattatgcgtgtgaacgtggataaagttctggaacgtgatcagaaactg   
 E  V  V  D  I  M  R  V  N  V  D  K  V  L  E  R  D  Q  K  L  
agcgaactggatgatcgtgcagatgcactgcaggcaggcgcaagccagtttgaaaccagc   
 S  E  L  D  D  R  A  D  A  L  Q  A  G  A  S  Q  F  E  T  S  
gcagcaaaactgaaacgtaaatattggtggaaaaacctgaaaatgatgattatcctgggt   
 A  A  K  L  K  R  K  Y  W  W  K  N  L  K  M  M  I  I  L  G  
gtgatttgcgccattattctgattatcatcatcgtgtattttagcacctaa   
 V  I  C  A  I  I  L  I  I  I  I  V  Y  F  S  T  -   
 
 
A4. Codon optimised sequence encoding human Rpn13 C-terminal domain  
agtccgagtccggcaccgtcaagcggtaatggtgcaagcaccgcagcaagcccgacccag   
 S  P  S  P  A  P  S  S  G  N  G  A  S  T  A  A  S  P  T  Q  
ccgattcagctgagcgatctgcagagtattctggcaaccatgaatgttccggcaggccct   
 P  I  Q  L  S  D  L  Q  S  I  L  A  T  M  N  V  P  A  G  P  
gcgggtggtcagcaggttgatctggcaagcgttctgacaccggaaattatggcaccgatt   
 A  G  G  Q  Q  V  D  L  A  S  V  L  T  P  E  I  M  A  P  I  
ctggccaatgcagatgttcaagaacgtctgctgccgtatctgccgagcggtgaaagcctg   
 L  A  N  A  D  V  Q  E  R  L  L  P  Y  L  P  S  G  E  S  L  
ccgcagaccgcagatgaaattcagaataccctgaccagtccgcagtttcagcaggcactg   
 P  Q  T  A  D  E  I  Q  N  T  L  T  S  P  Q  F  Q  Q  A  L  
ggtatgtttagcgcagcactggccagcggtcagctgggtccgctgatgtgtcagtttggt   
 G  M  F  S  A  A  L  A  S  G  Q  L  G  P  L  M  C  Q  F  G  
ctgcctgcagaagcagttgaagcagcaaataaaggtgatgttgaagcatttgcaaaagcc   
 L  P  A  E  A  V  E  A  A  N  K  G  D  V  E  A  F  A  K  A  
atgcagaataatgcaaaaccggaacagaaagaaggcgacaccaaagataaaaaagacgaa   
 M  Q  N  N  A  K  P  E  Q  K  E  G  D  T  K  D  K  K  D  E  
gaggaagatatgagcctggactaa   
 E  E  D  M  S  L  D  -   




B1. NMR theory 
 
Nuclear magnetic resonance (NMR) is a phenomenon that arises as a result of the 
reorientation of nuclear spins in an applied magnetic field (Campbell, 2012). Nuclei of 
certain isotopes have an intrinsic angular momentum referred to as ‘spin’. The 
magnitude of spin angular momentum is given by 
 
[I (I + 1)]1/2 ħ 
and is quantized in units of ħ (= h/2π, h is Planck’s constant). The spin quantum number 
I of a nucleus is determined by the number of unpaired protons and neutrons and can 
take one of the following values 
 
I = 0, 1/2, 1, 3/2, 2, …, 
A nucleus of spin I can have 2I + 1 energy levels when placed in a static magnetic field. 
Many isotopes used in protein NMR spectroscopy have nuclei with I = 1/2 and have only 
two energy levels. In the absence of a magnetic field all orientations of a spin I nucleus 
have the same energy. In the presence of a magnetic field (B0), a spin-1/2 nucleus (1H 
nucleus for example) can have only two orientations (along or against the direction of 
the static field) (Fig. B1.1A). These two states are separated by an energy ΔE. The 
resonance condition occurs when the application of a wave of frequency ν causes nuclei 
to ‘flip’ from the lower energy level to the upper one, provided ΔE = hν. The large 
number of spins present in a sample at equilibrium gives rise to bulk magnetization, a 
vector with magnitude M. The component of Mz along the static field B0 (Fig. B1.1B) is 
proportional to the population difference between the two energy levels (Hore, 1995; 




Figure B1.1- Energy levels and bulk magnetization. (A) Spin 1/2 nuclei have two 
possible energy states when interacting with a magnetic field (B0). At equilibrium, 
magnetic dipoles have a slight preference for the lower energy ground state (ng) over the 
upper state (nu) due to the Boltzmann distribution. (B) The bulk magnetization vector  
shown as a blue arrow along the z axis (Campbell, 2012; Keeler, 2005). 
 
 
A nucleus with finite spin has a magnetic moment (µ) which can interact with an 
applied static field. µ is directly proportional to I, and is given by, 
 
µ =  γI 
where, γ is the gyromagnetic ratio. The ‘spin’ of µ confers on it the property of angular 
momentum, which leads to precession (Fig. B1.2). The frequency of precession is given 
by, 
 
ω = 2πν = γB0 
where ω is the Larmor frequency (angular frequency) and ν is the frequency in cycles 
per second (Hz). The gyromagnetic ratio varies for different nuclei and gives rise to 






Figure B1.2- Larmor precession. The magnetic moment (µ) shown as a green arrow, 
rotates around the z-axis at a constant angle in the presence of B0 (Keeler, 2005).  
 
Table B1.1- Spin quantum numbers, gyromagnetic ratios, NMR frequencies (at 9.4 











1H 1/2 26.75 400.0 99.985 
2H 1 4.11 61.4 0.015 
13C 1/2 6.73 100.6 1.108 
14N 1 1.93 28.9 99.63 
15N -1/2 -2.71 40.5 0.37 
19F 1/2 25.18 376.5 100.0 
 
The application of a radiofrequency pulse at a precise frequency perpendicular to Bo 
will give rise to a field B1, which in turn induces phase coherence in the x-y plane 
generating transverse magnetization (Mxy). In a similar manner, the application of 
different kinds of pulse sequences will effect the bulk equilibrium magnetization (Mo) 
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in ways that can be used to obtain information about the sample under investigation. 
The B1 field causes Mo to rotate at the Larmor frequency given by, 
 
ω = γB1 
This precessing magnetisation gives rise to a transient signal called the free induction 
decay (FID), and is detected by a coil in the x-y plane. The FID is a time-domain signal, 
and can be converted into a spectrum of frequencies by Fourier transformation (Fig. 




Figure B1.3- Fourier transformation. Fourier transformation is a mathematical 
process by which a time-domain signal such as a free induction decay (FID) can be 
converted into the frequency-domain, a distribution of frequencies that constitute an 
NMR spectrum.  Figure adapted from Keeler (2005).   
 
The NMR resonance frequency of a nucleus within a molecule is given by, 
 ν = 𝛾B2𝜋 
This demonstrates that the NMR frequency of a nucleus depends on its gyromagnetic 
ratio and the field strength it experiences. However, resonances frequencies also depend 
upon the local electron distribution, which can reduce the effective field experienced by 
the nucleus. This effect is referred to as the ‘chemical shift’, and gives rise to separately 
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detectable NMR signals within a molecule (Hore, 1995; Campbell, 2012). The effective 
field experienced by a nucleus is therefore given by, 
B = B0 (1 - σ) 
where σ is the shielding constant. Thus the actual NMR frequency of a nucleus 
becomes,  
ν = 𝛾B!  (1− 𝜎)2𝜋  
In practice, however, absolute shifts are not used. Instead chemical shifts are defined in 
terms of the difference in resonance frequencies between a nucleus of interest and a 
reference nucleus, and is given by, 
δ = 10! (ν− ν!"#)ν!"#  
and δ is independent of the magnetic field. It is reported in parts per million, or ppm 
(Hore, 1995). Therefore, resonances can be resolved and assigned based on their 
chemical shifts, this provides means to understand molecular structure and follow 
interactions based on perturbations in chemical shifts observed upon binding.  
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Appendix C 	  
Assignments of backbone amide resonances corresponding to residues within the SGTA 
C-terminal domain. These assignments was carried out by Dr Santiago Martinez-
Lumbreras at the Department of Chemistry, King’s College London. 
 
 
















































Figure D1- N-terminal domain correlation times in the context of different SGTA 
constructs. Correlation times (τc) of the N-terminal domain (shown above) when 
present in the context of three different SGTA constructs (Nter, Nter-TPR and full-
length) were estimated from the T1/T2 values using the following equation 
𝜏! ≈ 14𝜋𝜐! 6𝑇!𝑇! − 7 
15N relaxation experiments on the Nter, Nter-TPR and full-length SGTA constructs were 
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Figure D2- TPR domain correlation times in the context of different SGTA 
constructs. Correlation times (τc) of the TPR domain (shown above) when present in 
the context of three different SGTA constructs (TPR, Nter-TPR and full-length) were 
estimated from the T1/T2 values using the following equation 
𝜏! ≈ 14𝜋𝜐! 6𝑇!𝑇! − 7 
15N relaxation experiments on the TPR, Nter-TPR and full-length SGTA constructs 
were acquired at spectrometer frequencies (𝜐!) of 700 MHz, 700 MHz and 950 MHz, 
respectively. 
 
